WO2005073247A1 - Conjugues d'acides amines et de peptides d'amiloride et methodes d'utilisation - Google Patents

Conjugues d'acides amines et de peptides d'amiloride et methodes d'utilisation Download PDF

Info

Publication number
WO2005073247A1
WO2005073247A1 PCT/US2005/001564 US2005001564W WO2005073247A1 WO 2005073247 A1 WO2005073247 A1 WO 2005073247A1 US 2005001564 W US2005001564 W US 2005001564W WO 2005073247 A1 WO2005073247 A1 WO 2005073247A1
Authority
WO
WIPO (PCT)
Prior art keywords
gly
conjugate
peptidase
peptide
amiloride
Prior art date
Application number
PCT/US2005/001564
Other languages
English (en)
Inventor
Fredric A. Gorin
Michael H. Nantz
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2005073247A1 publication Critical patent/WO2005073247A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • High-grade malignant gliomas i.e., astrocytomas
  • astrocytomas are the most commonly occurring type of lethal adult brain tumor and are increasing in incidence (Legler et al, J. National Cancer Inst., 91:1382-1390 (1999)).
  • the median survival is approximately 9-12 months following diagnosis, as the tumors are usually refractory to aggressive multimodal therapy (Brandes et al, Amer. J. Clin. One, 22:387-390 (1999)).
  • Gliomas exhibit increased glycolytic fluxes associated with elevated lactate/pyruvate ratios that would indicate an acidotic intracellular H (pH;) (Miccoli et al, Biochem.
  • Glycolytic rates are optimal at an alkalotic Hj and inhibition of glycolytic flux is sensitive to modest reductions in pH ; . (Dobson et al., Amer. J. Physiol, 250:R71-76 (1986)). Obligate tumor DNA synthesis and cell cycle progression are also optimal at an alkalotic pHj (Hasuda et al, One. Res., V6:259-268 (1994)). For example, a reduction in pH has been associated with reduced rates of proliferation and growth arrest in transformed cell types (Musgrove et al, Exp. Cell Res., 172:65-75 (1987); Rotin et al, Cancer Res., 49:205-211 (1989); Horvat et al, Eur. J. Cancer, 29 A 132-217 (1992)).
  • PFK phosphofructokinase
  • PFK glycolytic enzyme phosphofructokinase
  • hexokinase activity and intracellular distribution are affected by even modest reductions from an optimal alkaline pHj (Miccoli et al, id), as its activity is required for glucose entry into the glycolytic pathway and is increased in gliomas and in many other proliferative tumors (Katabi et al, Hum. Gene Ther., 10:155-164 (1999); Sebastian et al, Tumour Biol, 19:253-260 (1998)).
  • these tumors may be particularly sensitive to pHj reductions.
  • the alkalosis in glioma cells was reported to result from the persistent activation of NHEl, a ubiquitously-expressed type 1 Na -H + exchanger involved in intracellular pH and volume regulation (McLean et al. , supra; Hegde et al. , J. Pharmacol. Exp. Ther. , 310:67-74 (2004)).
  • the Na + -H + exchanger (NHE) represents a family of sodium-dependent transport proteins that participate in various cellular functions (Or ⁇ owsM et al. , JBiol. Chem.,
  • NHE1-7 Seven isoforms (i.e., NHE1-7) have been identified (Numata et al, JBiol. Chem., 276:17387-17394 (2001); Brett etal, Am. J. Physiol, 282:C1031-1041 (2002); Slepkov et al, Biochem. Cell Biol, 80:499-508 (2002)).
  • NHEl andNHE5-7 are particularly important in maintaining the pH; in human heart and brain.
  • NHEl activity has also been observed in other cancer cell lines, including colon and bladder (Bischo f et al, Bwchimica et Biophysica Acta, 1282:131-139 (1996); Boyer et al, Cancer Res., 52:4441-4447 (1992)).
  • Amiloride (3,5-diamino-6-chlo ⁇ -N-(diaminomethylene)pyrazinecarboxamide), originally developed as an antidiuretic drug, displays antiproliferative effects on several cancer cell lines (Horvat et al, id; Hasuda et al, id; Garcia-Canero et al, Tox.
  • amiloride is thought to block tumor cell proliferation through inhibition of specific ion transport systems; in particular, amiloride displays inhibitory activity toward several classes of Na + -dependent membrane transporters, including NHEl, NCX (a Na + -Ca + exchanger), the Na7K + ⁇ ATPase, Na + - coupled solute transport, voltage-gated Na + channels, etc.
  • NHEl a Na + -dependent membrane transporters
  • NCX a Na + -Ca + exchanger
  • Na7K + ⁇ ATPase Na + - coupled solute transport
  • voltage-gated Na + channels etc.
  • BBB blood brain barrier
  • amiloride derivatives have been synthesized and their activities on ion transporters and glioma cells have been determined. However, such amiloride derivatives are also unsuitable as effective drugs for cancer therapy due to their non-specificity, toxicity, and/or inability to access the central nervous system (i.e., cross the BBB).
  • Agents that selectively inhibit NHE, such as cariporide do not kill glioma cells and direct acidification does not kill glioma cells (Hegde et al, J. Pharmacol. Exp. Ther., 310:67- 74 (2004)). Additional inhibition of NCX is required to confer cytoxicity to cancer cells as is observed with amiloride and dichlorobenzamil, which inhibit both NHE and NCX.
  • Amiloride and dichlorobenzamil are hydrophobic compounds that are rapidly taken up by glioma cells that likely contribute to their nonspecific toxicity (Palandoken et al, J. Pharmacol. Exp. Ther., Oct. 27; Epub. (2004)). Although conjugation of alkyl, alkenyl, or benzyl moieties to either the C(2) guanidine group or the C(5) amino group of amiloride has been reported to increase the inhibitory efficacy of NHEl and/or other ion transporters (e.g., NCX) (LAllemain et al, J. Biol.
  • amiloride derivatives e.g., amiloride conjugates
  • target particular cells and/or tissues with high specificity and potency (2) are low in toxicity to non-targeted cells and/or tissues; (3) are able to be transported across the BBB to access the central nervous system; and (4) kill tumor cell populations residing in hypoxic- ischemic tumor microenvironments that are normally resistant to conventional chemotherapy or radiotherapy.
  • the present invention satisfies this and other needs.
  • amiloride conjugates exhibit high specificity and potency, low toxicity, and are transported across the BBB into the central nervous system.
  • the amiloride conjugates of the present invention have the following advantages: (1) amiloride-peptide conjugates with peptidase cleavage sites are not only capable of traversing the BBB, but upon cleavage by brain- or tumor-specific peptidases in the central nervous system, release hydrophilic proteolytic products (e.g., C2 /n-Gly, C5 -Gly) that act at the tumor cell surface, thus minimizing toxic side-effects; (2) amiloride-peptide conjugates with peptidase cleavage sites are biologically inactive NHE inhibitor prodrugs that can be administered prior to the onset of ischemia and subsequently activated by peptidases selectively expressed by the ischemic tissue (e.g., brain, heart);
  • the present invention provides a conjugate having the formula:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the present invention provides a conjugate having the formula:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the present invention provides a conjugate having the formula: wherein Xi and X 2 are m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than or equal to 1.
  • the present invention provides a conjugate having the formula:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subj ect a therapeutically effective amount of a conjugate having the formula:
  • X is n mdependently selected amino acids and n is an integer greater than or equal to 1.
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • Xj and X 2 are m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than or equal to 1.
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula;
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the present invention also provides methods for administering hydrophobic amiloride-peptide conjugates that can then be converted in vivo to hydrophilic agents upon the action of a peptidase.
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide is selectively cleaved by a peptidase in the central nervous system.
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • Xj and X 2 are peptides comprising m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than 1, and wherein at least one of the peptides is selectively cleaved by a peptidase in the central nervous system.
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide is selectively cleaved by a peptidase in the ischemic tissue.
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide is selectively cleaved by a peptidase in the ischemic tissue.
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject p ⁇ or to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • Xi and X 2 are peptides comprising m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than 1, and wherein at least one of the peptides is selectively cleaved by a peptidase in the ischemic tissue.
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherem the peptide is selectively cleaved by a peptidase in the ischemic tissue.
  • kits for administering hydrophobic amiloride-peptide conjugates that can then be converted in vivo to hydrophilic agents upon the action of a peptidase.
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • Xi and X 2 are peptides comprising m and n independently selected amino acids, respectively; and m and n are independently selected integers greater than 1, and at least one of the peptides contains a cleavage site recognized by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • the present invention proides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • X 1 and X 2 are peptides comprising m and n independently selected amino acids, respectively; and m and n are independently selected integers greater than 1, and at least one of the peptides contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula: wherein X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • Figure 1 illustrates a model for tumor cell death induced by the amiloride conjugates of the present invention.
  • Figure 1 A increased activation of NHEl (1) in tumor cells causes intracellular alkalosis with an accumulation of [Na + ]j and [Ca 2+ ]j.
  • Figure IB shows that the cell death is achieved by the inhibition of NCX (2), which results in [Ca 2+ ]j accumulation, and the inhibition of NHEl, which results in a reduction in pH, impairing glycolysis and leading to the release of additional calcium from energetically sensitive intracellular stores such as the mitochondria (mito, 4) and the endoplasmic reticulum (ER, 5).
  • mitochondria mitochondria
  • ER endoplasmic reticulum
  • Figure 2A shows the elevated levels of [Ca 2+ ji in U87 gliomas at ⁇ H 0 7.4 and 6.8. NHEl inhibition with HOE694 did not alter [Ca 2+ ]j.
  • Figure 2B shows that pretreatinent with DCB caused FCCP-induced [Ca 2+ ]i to increase to cytotoxic levels that preceded the leakage of fura-2 from dying cells.
  • Figure 2C shows that DCB is an NCX inhibitor that at concentrations between 50-lOOnM also inhibits NHEl and acidifies U87 glioma cells loaded with BCECF.
  • Figure 2D shows that DCB at >20 ⁇ M killed glioma cells. Cell death was minimally affected by caspase inhibitors.
  • Figure 3 shows the tumor growth kinetics of intracerebral U87 glioma xenografts with different intracerebral treatments.
  • Figure 4 shows that 100 mM amiloride in the reservoir of an Alzet pump optimally releases 276 pmol/24h for 14 days. A total of 3.3 nmoles of amiloride were infused intracerebrally over 12 days with maximal accumulation occurring by 8 days.
  • Figure 5 shows the behavioral testing over 9 days of rats receiving intrathecal amiloride infusion. In Figure 5 A, amiloride did not affect balance and fine motor coordination in tumor-implanted rats.
  • Figure 5B shows that amiloride treatment did affect spatial learning performance in tumor-implanted rats.
  • Figure 5C shows that amiloride treatment did not affect memory in a spatial learning task in tumor-implanted rats,
  • Figure 6 shows an X-ray crystal structure of C(5)-amino acid conjugate 3a as its benzyl ester.
  • Figure 7 shows a model for ion transporter activation during ischemia-reperfusion injury.
  • Figure 8 shows a model of the amiloride-peptide conjugates of the present invention being enzymatically activated to inhibit sodium-proton exchange.
  • Figure 9 shows fluorescent microscopy images of U87 glioma cells following 90 min incubation with (A) 50 ⁇ M amiloride; (B) 50 ⁇ M ethylisopropylamiloride (EIPA); or following 180 min incubation with (C) 50 ⁇ M compound 3a.
  • a single trypan- positive, dying or dead U87 cell demonstrates intracellular accumulation of compound 3a (arrow).
  • Figure 10 shows an overlay of MM2-minimized structures with hydrogens omitted for clarity (obtained from Chem3D).
  • Figure 11 shows a [Leu] 5 -enkephalin amide analog that incorporates C2,5 -(Gly) 2 into the third residue.
  • conjugate refers to a chemical compound that has been formed by the joining or attachment of two or more compounds.
  • a conjugate of the present invention comprises an amino acid or peptide covalently attached to amiloride or other suitable therapeutic agent.
  • amino acid refers to naturally occurring ⁇ -amino acids and their stereoisomers, as well as unnatural amino acids such as amino acid analogs, amino acid mimetics, synthetic amino acids, ⁇ -amino acids, ⁇ -amino acids, N-methyl amino acids, and N-substituted glycines in either the L- or D-configuration that function in a manner similar to the naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ - carboxyglutamate, and O-phosphoserine.
  • “Stereoisomers” of naturally occurring amino acids refers to mirror image isomers of the naturally occurring amino acids, such as D-amino acids.
  • “Amino acid analogs” refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
  • amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
  • amino group is bonded to the 0-carbon atom of the carboxyl group such that there are two carbon atoms between the amino and carboxyl groups.
  • amino group is bonded to the ⁇ -carbon atom of the carboxyl group such that there are three carbon atoms between the amino and carboxyl groups.
  • Suitable side chains (e.g., R groups) for ⁇ - or ⁇ - amino acids include, but are not limited to, side chains present in naturally occurring amino acids and unnatural amino acids such as amino acid analogs, amino acid mimetics, synthetic amino acids, N-methyl amino acids, and N-substituted glycines.
  • N-substituted glycine refers to a glycine amino acid where an amino acid side chain is attached to the glycine nitrogen atom.
  • Suitable amino acid side chains include, but are not limited to, side chains present in naturally occurring amino acids and side chains present in unnatural amino acids such as amino acid analogs, amino acid mimetics, synthetic amino acids, /3-amino acids, and ⁇ -amino acids.
  • N- substituted glycines suitable for use in the present invention include, without limitation, N-(2- aminoethyl)glycine, N-(3-aminopropyl)glycine, N-(2-methoxyethyl)glycine, N- benzylglycine, (S)-N-(l-phenylethyl)glycine, N-cyclohexylmethylglycme, N-(2- ⁇ henylethyl)glycine, N-(3-phenylpropyl)glycine, N-(6-aminogalactosyl)glycine, N-(2-(3'- indolylethyl)glycine, N-(2- 5 -methoxyphenylethyl))glycme,N-(2-(p- chlorophenylethyl)glycine, and N-[2-(p-hydroxyphenylethyl)] glycine.
  • Such ⁇ -substituted glycines can have an L- or D-configuration.
  • ⁇ -substituted glycine oligomers referred to herein as "peptoids,” have been shown to be protease resistant (Miller et al , Drug Dev. Res. , 35:20-32 (1995)). As such, an amiloride-peptoid conjugate is within the scope of the present invention.
  • Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
  • D-amino acids are represented herein by a lower-case one-letter amino acid symbol (e.g., r for D-arginine), whereas L-amino acids are represented by an upper case one-letter amino acid symbol (e.g., R for L ⁇ arginine).
  • the chemically similar amino acids include, but are not limited to, naturally occurring amino acids such as c-amino acids having an L-configuration, stereoisomers of naturally occurring amino acids such as ⁇ - amino acids having a D-configuration, and unnatural amino acids such as amino acid analogs, amino acid mimetics, synthetic amino acids, / 5-amino acids, and ⁇ -amino acids, in either the L- or D-configuration.
  • naturally occurring amino acids such as c-amino acids having an L-configuration
  • stereoisomers of naturally occurring amino acids such as ⁇ - amino acids having a D-configuration
  • unnatural amino acids such as amino acid analogs, amino acid mimetics, synthetic amino acids, / 5-amino acids, and ⁇ -amino acids, in either the L- or D-configuration.
  • unnatural amino acids of Liu and Lam are suitable for use in the present invention.
  • substitutions may be made wherein an aliphatic amino acid (G, A, I, L, or V) is substituted with another member of the group.
  • an aliphatic polar-uncharged group such as C, S, T, M, N, or Q, may be substituted with another member of the group; and basic residues, e.g., K, R, or H, may be substituted for one another.
  • an amino acid with an acidic side chain, E or D may be substituted with its uncharged counterpart, Q or N, respectively; or vice versa.
  • Each of the following eight groups contains other exemplary amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins, 1984).
  • peptide refers to a compound made up of a single chain of D- or L- amino acids or a mixture of D- and L-amino acids joined by peptide bonds. Generally, peptides are about 2 to about 50 amino acids in length. Preferably, the peptides of the present invention are conjugated via a peptide bond to the C(2) and/or C(5) glycine of C2 ⁇ -Gly or C5 ⁇ zr ⁇ -Gly.
  • the peptides can also be directly conjugated to the C(2) and/or C(5) position of amiloride (e.g., no glycine spacer.)
  • the peptides of the present invention are preferably between 2 and 25 amino acids, more preferably between 2 and 10 amino acids, and most preferably between 2 and 8 amino acids in length.
  • the free amino-terminus and/or carboxyl-terminus on peptides are protected by an amide, a methyl ester, a succinyl, or an acetyl group. Further chemical modifications at positions 1, 3, 4, or 6 of the amiloride ring structure do not fundamentally alter the properties conferred by the primary chemical additions to the guandine moiety at C(2) and/or the amine moiety at C(5).
  • linker and “spacer” are used interchangeably herein to refer to an amino acid or a doubly funcfionalized hydrocarbon chain that connects a peptide or an active pharmaceutical compound to the C(2) and/or C(5) position of amiloride.
  • the amino acid linker on amiloride is glycine, e.g., C2 ⁇ m-Gly, C5 m-Gly, or C2,5 ⁇ m-(Gly) 2 .
  • the doubly functionalized hydrocarbon chain on amiloride is a diamine, e.g., NH 2 - (CH2) n -NH 2 , wherein n is from 1 to 6.
  • the peptide connected to amiloride via a linker is selectively cleaved by a peptidase.
  • the active pharmaceutical compound connected to amiloride via a linker is tamoxifen, e.g., for breast cancer therapy.
  • cancer refers to any of various malignant neoplasms characterized by the proliferation of cells with altered cell cycle regulation that tend to invade surrounding tissue and metastasize to new body sites.
  • examples of different types of cancer suitable for treatment using the present invention include, but are not limited to, lung cancer, breast cancer, bladder cancer, thyroid cancer, liver cancer, pleural cancer, pancreatic cancer, ovarian cancer, cervical cancer, testicular cancer, colon cancer, B-cell lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, fibrosarcoma, neuroblastoma, glioma, melanoma, monocytic leukemia, myelogenous leukemia, meningioma, schwannoma, and oligodendroglioma.
  • central nervous system disease or disorder refers to a disease or disorder that affects any component of the brain (e.g., the cerebral hemispheres, diencephalon, brain stem, cerebellum), spinal cord, or a combination thereof.
  • Examples of different types of central nervous system diseases or disorders suitable for treatment using the present invention include, but are not limited to, brain diseases such as akinetic mutism, amblyopia, amnesia, auditory diseases, basal ganglia diseases, brain abscess, brain damage, brain death, metabolic brain diseases, brain edema, brain injuries, brain neoplasms, cerebellar diseases, cerebrovascular disorders, dementia, diffuse cerebral sclerosis of Schilder, encephalitis, encephalomalacia, epilepsy, headache disorders, hydrocephalus, hypothalamic diseases, intracranial hypertension, intracranial hypotension, Kluver-Bucy syndrome, neuroaxonal dystrophies, subdural effusion, and thalamic diseases; central nervous system infections such as bacterial, fungal, parasitic, and viral infections, subdural empyema, encephalomyelitis, epidural abscess, meningitis, meningoencephalitis, myelitis, perimeningeal infections
  • ischemia refers to an interruption or decrease in blood supply to a bodily tissue or organ caused by constriction or obstruction of blood vessels, leading to oxygen deprivation of the tissue or organ, which can result in tissue or organ damage.
  • myocardial ischemia refers to a condition characterized by a blockage or constriction of one or more of the coronary arteries that can occur with atherosclerotic plaque occlusion or rupture.
  • perfusion refers to the restoration of blood flow to a bodily tissue or organ that has had its blood supply cut off, leading to reoxygenation of the tissue or organ, such as, e.g., after a heart attack.
  • ischemia-reperfusion injury refers to tissue or organ damage caused by oxygen deprivation followed by reoxygenation of the tissue or organ.
  • reperfusion with subsequent reoxygenation of the tissue or organ causes additional tissue or organ injury such as, e.g., oxidative stress.
  • peptidase refers to any of various enzymes that catalyze the degradation of peptides, polypeptides, and proteins by hydrolyzing at least one of their peptide bonds.
  • Suitable peptidases for use in the present invention include, but are not limited to, endopeptidases (e.g., serine proteases and metalloproteinases) and exopeptidases (e.g., carboxypeptidases and aminopeptidases).
  • peptidases such as opioid neuropeptide peptidases (e.g., enkephalinases), metalloproteinases (e.g., matrix metalloproteinases, disintegrin-metalloproteinases (ADAMs)), plasminogen activators, cathepsins, calpains, and caspases are suitable for use in the present invention.
  • opioid neuropeptide peptidases e.g., enkephalinases
  • metalloproteinases e.g., matrix metalloproteinases, disintegrin-metalloproteinases (ADAMs)
  • plasminogen activators e.g., cathepsins, calpains, and caspases
  • cathepsins calpains
  • caspases plasminogen activators
  • cathepsins cathepsins
  • calpains calpains
  • caspases plasminogen activators
  • cathepsins cathe
  • the peptidase contains an arginine in the active site that interacts with the carboxyl-terminal carboxylate of peptide substrates. Peptidase activity is specifically directed toward the selective cleavage on the amino side of hydrophobic residues.
  • matrix metalloproteinase refers to members of a family of proteolytic enzymes that have a zinc ion at their active sites and can degrade collagen, elastin, and other components of the extracellular matrix.
  • the matrix metalloproteinase is MMP-2 or MMP-9.
  • the substrate specificity of MMP-2 is collagen (e.g., types IV, V, VII, and X), elastin, type I gelatin, and peptide fragments thereof containing the MMP-2 cleavage site.
  • the term "selectively cleaved” refers to the hydrolysis of a peptide bond by a protease upon recognition of a specific amino acid residue or amino acid sequence in a peptide, polypeptide, or protein.
  • trypsin selectively cleaves peptide bonds on the carboxyl-terminal side of lysine (K) and arginine (R) amino acid residues.
  • Chymotrypsin selectively cleaves peptide bonds on the carboxyl-terminal side of phenylalanine (F), tryptophan (W), and tyrosine (Y) residues.
  • Enkephalinase selectively cleaves peptide bonds on the amino-terminal side of hydrophobic residues.
  • a therapeutically effective amount refers to the amount of an amiloride conjugate of the present invention that is capable of achieving a therapeutic effect in a subject in need thereof.
  • a therapeutically effective amount of an amiloride conjugate of the present invention can be the amount that is capable of treating cancer, treating a central nervous system disease or disorder, or preventing or reducing ischemia-reperfusion injury.
  • administering means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intraarterial, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to a subject.
  • Adminsitration is by any route including parenteral and transmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • injection is to treat a tumor, e.g., induce apoptosis
  • administration may be directly to the tumor and or into tissues surrounding the tumor.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • the present invention provides novel amiloride conjugates that advantageously display high specificity and potency, are low in toxicity, and traverse the blood brain barrier (BBB) into the central nervous system, as well as methods of use thereof.
  • BBB blood brain barrier
  • Amiloride is an FDA-approved diuretic that inhibits tumor cell proliferation and exhibits cytotoxic effects on tumor cells at high concentrations.
  • amiloride due to the hydrophobic nature of amiloride (i.e., high toxicity associated with significant intracellular accumulation), its low potency for producing cytotoxic effects (i.e., high (>500 ⁇ M) concentrations required), and its inability to cross the blood brain barrier (BBB), amiloride is unsuitable as an effective drug for treating cancers such as gliomas.
  • the present invention provides novel amino acid and peptide conjugates of amiloride that are potent and effective NHEl and or NCX inhibitors, display cytotoxic and/or anitproliferative effects on tumor cells such as glioma cells, are hydrophilic (i.e., low toxicity), are selectively cleaved by brain-specific, tumor-specific, or tissue injury-induced peptidases, and are able to cross the BBB.
  • amiloride conjugates of the present invention have the following advantages: (1) amiloride-peptide conjugates with peptidase cleavage sites are not only capable of traversing the BBB, but upon cleavage by brain- or tumor-specific peptidases in the central nervous system, release hydrophilic proteolytic products (e.g., C2 ⁇ -Gly, C5 - Gly) that act at the tumor cell surface, thus minimizing toxic side effects; and (2) the conjugates kill tumor cell populations residing in hypoxic-ischemic tumor microenvironments (i.e., tumor cells with little or no blood supply) that are normally resistant to conventional chemotherapy or radiotherapy.
  • hypoxic-ischemic tumor microenvironments i.e., tumor cells with little or no blood supply
  • amiloride conjugates of the present invention particularly useful therapeutic agents for the treatment of cancer (e.g., glioma, breast cancer) as well as other diseases and disorders such as central nervous system disorders (e.g., traumatic brain injury, seizure), stroke, cardiac arrthymia, etc.
  • cancer e.g., glioma, breast cancer
  • other diseases and disorders e.g., central nervous system disorders (e.g., traumatic brain injury, seizure), stroke, cardiac arrthymia, etc.
  • novel amiloride conjugates of the present invention are also useful as therapeutic agents for the prevention or reduction of ischemia-reperfusion injury, e.g., to brain or heart tissue.
  • ischemia-reperfusion injury e.g., to brain or heart tissue.
  • inhibition of Na + -H + exchangers such as NHEl are important in reducing tissue damage during ischemia-reperfusion injury
  • currently available pharmacological inhibitors of NHEl such as amiloride are unable to access the ischemic tissue due to severely compromised tissue perfusion.
  • the present invention overcomes this limitation by advantageously providing a biologically inactive NHEl inhibitor prodrug (e.g., an amiloride-peptide conjugate) that is administered prior to the onset of ischemia.
  • peptidases selectively expressed or activated by the ischemic tissue activate the prodrug, thereby preventing or reducing ischemia-reperfusion injury in the affected tissue.
  • the peptidases can selectively release hydrophilic proteolytic products (e.g., C2 ⁇ m-Gly, C5 ⁇ m-Gly) from the prodrug that act at the cell surface of the ischemic tissue, thus minimizing toxic side effects.
  • hydrophilic proteolytic products e.g., C2 ⁇ m-Gly, C5 ⁇ m-Gly
  • the prodrugs described herein are particularly useful for preventing or reducing ischemia-reperfusion injury in brain or heart tissue.
  • the present invention provides a conjugate having the formula: NH (X)n H 2 N N NH 2 wherein X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • amino acid i.e., when n equals 1
  • peptide i.e., when n is greater than 1
  • X is a peptide comprising a combination of independently selected amino acids or a polymer of one amino acid.
  • the amino acids are selected from the group consisting of ⁇ -amino acids, (3-amino acids, ⁇ -amino acids, N-methyl amino acids, N-substituted glycines, and combinations thereof.
  • the amino acids are selected from the group consisting of L-amino acids, D-amino acids, and combinations thereof.
  • the ⁇ -amino acids are selected from the group consisting of alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, arginine, lysine, leucine, methionine, asparagine, proline, glutamine, serine, threonine, valine, tryptophan, hydroxyproline, tyrosine, and combinations thereof.
  • the amino acid or peptide is connected to the C(2) position of amiloride via a linker.
  • Suitable linkers include glycine and a diamine.
  • the linker is glycine.
  • n equals 1 and the amino acid is glycine, phenylalanine, (2,4-dichloro)-phenyialanine, serine, or O-henzyl serine.
  • X is a peptide and n is between 2 and 50, preferably between 2 and 25, more preferably between 2 and 10, and most preferably between 2 and 8.
  • the peptide contains one or more amino acids selected from the group consisting of (2,4-dichloro)-phenylalanine, 0-benzyl serine, and combinations thereof.
  • the peptide comprises a sequence having at least two glycine residues.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • the peptidase is an endogenous peptidase.
  • the peptidase can be an exogenous peptidase.
  • the peptide is selectively cleaved by an enkephalinase.
  • the peptide can contain an amino acid sequence recognized by an enkephalinase or a related endopeptidase such as a sequence comprising an enkephalin, a derivative thereof, or an analog thereof (e.g., [Leu] 5 -enkephalin amide).
  • the peptide is selectively cleaved by a metalloproteinase such as a matrix metalloproteinase (e.g., MMP-2, MMP-9) or a disintegrin-metalloproteinase (e.g., ADAM).
  • a metalloproteinase such as a matrix metalloproteinase (e.g., MMP-2, MMP-9) or a disintegrin-metalloproteinase (e.g., ADAM).
  • the peptide is selectively cleaved by a plasminogen activator, a cathepsin, a calpain, or a caspase.
  • the peptide is selected from the group consisting of Gly-Gly-Gly-Gly-Phe-Leu-OH, Tyr-D-Ala-Gly-Phe-Gly-NH 2 , Glu-Ser-Leu-Ala-Tyr-Tyr-Thr-Ala-Gly-NH 2 , Arg-Ser-Leu-Ser-Arg-Leu-Thr-Ala-Gly-NH 2 , Glu-Ser-Leu-D-Ala-Tyr-Tyr-Thr-Ala-Gly-NH 2 , Arg-Ser-Leu-Ser-Arg-D-Leu-Thr-Ala-Gly-NH 2 , and Arg-Ser-Leu-Ser-Arg-Leu-Thr-A
  • the conjugate has the formula:
  • the conjugate has the formula:
  • the present invention provides a conjugate having the formula:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the amino acid (i.e., when n equals 1) or peptide (i.e., when n is greater than 1) is conjugated to the C(5) position of amiloride via an amine bond.
  • X is a peptide comprising a combination of independently selected amino acids or a polymer of one amino acid.
  • the amino acids are selected from the group consisting of those amino acids described above.
  • the amino acid or peptide is connected to the C(5) position of amiloride via a linker. Suitable linkers are described above.
  • n 1 and the amino acid is glycine, phenylalanine, (2,4-dichloro)-phenylalanine, serine, or O-benzyl serine.
  • X is a peptide and n is between 2 and 50, preferably between 2 and 25, more preferably between 2 and 10, and most preferably between 2 and 8.
  • the peptide contains one or more amino acids selected from the group consisting of (2,4-dichloro)-phenylalanine, O-be zyl serine, and combinations thereof. [0079]
  • the peptide comprises a sequence having at least two glycine residues.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • a peptidase such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • Suitable peptidases and peptide sequences are described above.
  • the conjugate has the formula:
  • the conjugate has the formula:
  • the present invention provides a conjugate having the formula:
  • Xi and X 2 are m and n independently selected amino acids, respectively, and m sad n are independently selected integers greater than or equal to 1.
  • the Xj amino acid (i.e., when m equals 1) or peptide (i.e., when m is greater than 1) is conjugated to the C(2) position of amiloride via an amide bond and the X 2 amino acid (i.e., when n equals 1) or peptide (i.e., when n is greater than 1) is conjugated to the C(5) position of amiloride via an amine bond.
  • j and X 2 are either identical or different peptides comprising a combination of independently selected amino acids or a polymer of one amino acid.
  • the amino acids are selected from the group consisting of those amino acids described above.
  • the amino acid or peptide is connected to the C(2) and/or 0(5) position of amiloride via a linker. Suitable linkers are described above.
  • m and/or n equals 1 and the amino acid is glycine, phenylalanine, (2,4-dichloro)-phenylalanine, serine, and or O- benzyl serine.
  • Xi and X 2 are peptides and m and n are each independently between 2 and 50, preferably between 2 and 25, more preferably between 2 and 10, and most preferably between 2 and 8.
  • the peptide contains one or more amino acids selected from the group consisting of (2,4- dichloro)-phenylalanine, O-benzyl serine, and combinations thereof.
  • At least one of the peptides comprises a sequence having at least two glycine residues.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated dining tissue injury. Suitable peptidases and peptide sequences are described above.
  • the conjugate has the formula:
  • the present invention provides a conjugate having the formula:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the amino acid (i.e., when n equals 1) or peptide (i.e., when n is greater than 1) is conjugated to the C(2) position of one amiloride molecule via an amide bond and to the C(5) position of a second amiloride molecule via an amine bond.
  • X is a peptide comprising a combination of independently selected amino acids or a polymer of one amino acid.
  • the amino acids are selected from the group consisting of those amino acids described above.
  • the amino acid or peptide is connected to the C(2) position of one amiloride molecule via one linker and to the C(5) position of a second amiloride molecule via another linker. Suitable linkers are described above.
  • n 1 and the amino acid is glycine, phenylalanine, (2,4-dichloro)-phenylalanine, serine, or O-benzyl serine.
  • X is a peptide and n is between 2 and 50, preferably between 2 and 25, more preferably between 2 and 10, and most preferably between 2 and 8.
  • the peptide contains one or more amino acids selected from the group consisting of (2,4-dichloro)-phenylalanine, O-benzyl serine, and combinations thereof.
  • the peptide comprises a sequence having at least two glycine residues.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • a peptidase such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • Suitable peptidases and peptide sequences are described above.
  • the conjugate has the formula:
  • the present invention provides a method for treating cancer in a subj ect in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • the cancer is lung cancer, breast cancer, bladder cancer, thyroid cancer, liver cancer, pleural cancer, pancreatic cancer, ovarian cancer, cervical cancer, testicular cancer, colon cancer, B-cell lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, fibrosarcoma, neuroblastoma, glioma, melanoma, monocytic leukemia, myelogenous leukemia, meningioma, schwannoma, ohgodendroglioma, said combinations thereof.
  • the cancer is a glioma.
  • the cancer is treated by killing cancer cells, inhibiting the proliferation of cancer cells, or a combination thereof.
  • X is a peptide and n is greater than 1, and X is selectively cleaved by a peptidase.
  • n is between 2 and 25, more preferably between 2 and 10, and most preferably between 2 and 8.
  • the method further comprises co-administering to the subject an agent (e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.) that activates an endogenous peptidase (e.g., a tumor-specific peptidase) which in turn selectively cleaves the peptide.
  • an agent e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.
  • an agent e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.
  • an endogenous peptidase e.g.
  • the method further comprises co-administering to the subject a peptidase that selectively cleaves the peptide.
  • a peptidase that selectively cleaves the peptide.
  • administration of the agent or peptidase may occur either at the same time as the administration of the amiloride conjugate, or may be administered sequentially in a predetermined order.
  • the co-administered agent or peptidase is present in an amount effective to increase the release of an active (i.e., bioactive) proteolytic product from the conjugate relative to the amount of release of the proteolytic product in the absence of the agent or peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2 ⁇ -amino acid cleavage product or a C2 ⁇ w-peptide cleavage product, a particularly preferred embodiment, the proteolytic product is C2 ⁇ -Gly.
  • the co-administered agent activates an endogenous peptidase such as, for example, an opioid neuropeptide peptidase (e.g., enkephalinase), a metalloproteinase (e.g., matrix metalloproteinase, disintegrin-metalloproteinase (ADAM)), a plasminogen activator, a cathepsin, a calpain, a caspase, or combinations thereof.
  • an opioid neuropeptide peptidase e.g., enkephalinase
  • a metalloproteinase e.g., matrix metalloproteinase, disintegrin-metalloproteinase (ADAM)
  • a plasminogen activator e.g., a plasminogen activator
  • cathepsin e.g., calpain
  • caspase e.g., a calpain
  • a caspase
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • Xis n independently selected amino acids and n is an integer greater than or equal to 1.
  • the cancer is any of the above-described cancers.
  • X is a peptide and n is greater than 1, and X is selectively cleaved by a peptidase.
  • the method can further comprise co-administering to the subject either an agent that activates an endogenous peptidase which in turn selectively cleaves the peptide, or, alternatively, a peptidase that selectively cleaves the peptide.
  • the co-administered agent or peptidase is present in an amount effective to increase the release of an active (i.e., bioactive) proteolytic product from the conjugate relative to the amount of release of the proteolytic product in the absence of the agent or peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C5 ⁇ »z-amino acid cleavage product or a C5 ⁇ -peptide cleavage product.
  • the proteolytic product is C5 ⁇ -Gly.
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • X and X 2 are m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than or equal to 1.
  • the cancer is any of the above-described cancers.
  • at least one of Xj and X 2 is a peptide, the peptide has greater than one amino acid (i.e., m and or n are independently greater than 1), and the peptide is selectively cleaved by a peptidase.
  • Xi and X 2 are different peptides that are selectively cleaved by different peptidases.
  • the method can further comprise co- administering to the subject either an agent that activates an endogenous peptidase which in turn selectively cleaves at least one of the peptides, or, alternatively, a peptidase that selectively cleaves at least one of the peptides.
  • the co- administered agent or peptidase is present in an amount effective to increase the release of an . active (i.e., bioactive) proteolytic product from the conjugate relative to the amount of release of the proteolytic product in the absence of the agent or peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2,5 -amino acid cleavage product or a C2,5 ⁇ »-peptide cleavage product, hi a particularly preferred embodiment, the proteolytic product is C2,5 ⁇ r ⁇ -(Gly) 2 .
  • the co- administered agent activates one or more of the above-described peptidases, or, alternatively, one or more of the above-described peptidases is co-administered to the subject.
  • the present invention provides a method for treating cancer in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the cancer is any of the above-described cancers
  • X is a peptide and n is greater than 1, and X is selectively cleaved by a peptidase.
  • the method can further comprise co-administering to the subject either an agent that activates an endogenous peptidase which in turn selectively cleaves the peptide, or, alternatively, a peptidase that selectively cleaves the peptide.
  • the co-administered agent or peptidase is present in an amount effective to increase the release of an active (i.e., bioactive) proteolytic product from the conjugate relative to the amount of release of the proteolytic product in the absence of the agent or peptidase.
  • an active i.e., bioactive
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2 ⁇ -amino acid cleavage product (e.g., C2 m-Gly), a C5 - amino acid cleavage product (e.g., C5 ⁇ -Gly), a C2 ⁇ -peptide cleavage product, a C5am ⁇ peptide cleavage product, or a combination thereof.
  • the proteolytic product is a combination of C2am-Gly and C5 «w-Gly.
  • the co-administered agent activates one or more of the above-described peptidases, or, alternatively, one or more of the above-described peptidases is co-administered to the subject.
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the central nervous system.
  • the central nervous system disease or disorder is any brain disease, central nervous system infection, movement disorder, or spinal cord disease described above.
  • the central nervous system disease or disorder is brain edema, traumatic brain injury, tissue hypoxia-ischemia, ischemia-reperfusion injury, epilepsy, brain tumor (e.g., glioma), or stroke.
  • the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the central nervous system peptidase.
  • the conjugate is a prodrug that releases an active (i.e., bioactive) proteolytic product upon selective cleavage by the central nervous system peptidase.
  • the prodrug is capable of crossing the blood brain barrier (BBB).
  • BBB blood brain barrier
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2am- amino acid cleavage product or a C2 ⁇ «z-peptide cleavage product.
  • the proteolytic product is C2 -Gly.
  • the peptide is a substrate for a central nervous system peptidase such as a brain-specific peptidase, a tumor-specific peptidase, a brain injury- activated calpain, a brain injury-activated caspase, a nervous system-specific peptidase, or combinations thereof, hi certain instances, the central nervous system peptidase is selected from the group consisting of an enkephalinase, a metalloproteinase such as MMP-2 or MMP- 9, and combinations thereof.
  • a central nervous system peptidase such as a brain-specific peptidase, a tumor-specific peptidase, a brain injury- activated calpain, a brain injury-activated caspase, a nervous system-specific peptidase, or combinations thereof.
  • the central nervous system peptidase is selected from the group consisting of an enkephalinase, a metalloproteinase such as MMP-2 or M
  • the peptide is selected from the group consisting of Gly-Gly-Gly-Gly-Phe-Leu-OH, Tyr-D-Ala-Gly-Phe-Gly-NH 2 , Glu-Ser-Leu-Ala-Tyr-Tyr- Thr-Ala-Gly-NH 2 , Arg-Ser-Leu-Ser-Arg-Leu-Thr-Ala-Gly-NH 2 , Glu-Ser-Leu-D-Ala-Tyr- Tyr-Thr-Ala-Gly-NH 2 , Arg-Ser-Leu-Ser-Arg-D-Leu-Thr-Ala-Gly-NH 2 , and Arg-Ser-Leu- Ser-Arg-Leu-Thr-Ala-Gly-Gly-NH 2 .
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula: wherein X is a peptide comprising n independently selected amino acids and n is an integer greater than 1 , and wherein the peptide contains a cleavage site recognized (i. e., selectively cleaved) by a peptidase in the central nervous system.
  • the central nervous system disease or disorder is any brain disease, central nervous system infection, movement disorder, or spinal cord disease described above.
  • the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the central nervous system peptidase.
  • the conjugate is a prodrug that releases an active (i.e., bioactive) proteolytic product upon selective cleavage by the central nervous system peptidase.
  • the prodrug is capable of crossing the BBB.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C5 ⁇ r ⁇ amino acid cleavage product or a C5 7n- ⁇ eptide cleavage product.
  • the proteolytic product is C5 ⁇ r ⁇ -Gly. Suitable central nervous system peptidases and peptide sequences are described above.
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • X and X 2 are peptides comprising m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than 1, and wherein the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the central nervous system.
  • the central nervous system disease or disorder is any brain disease, central nervous system infection, movement disorder, or spinal cord disease described above, hi another embodiment, the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the central nervous system peptidase.
  • the conjugate is a prodrug that releases an active (i.e., bioactive) proteolytic product upon selective cleavage by the central nervous system peptidase.
  • the prodrug is capable of crossing the BBB.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2,5 ⁇ -amino acid cleavage product or a C2,5 ⁇ m-peptide cleavage product.
  • the proteolytic product is C2,5 -(Gly) 2 . Suitable central nervous system peptidases and peptide sequences are described above.
  • the present invention provides a method for treating a central nervous system disease or disorder in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the central nervous system.
  • the central nervous system disease or disorder is any brain disease, central nervous system infection, movement disorder, or spinal cord disease described above.
  • the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the central nervous system peptidase.
  • the conjugate is a prodrug that releases one or more active (i.e., bioactive) proteolytic products upon selective cleavage by the central nervous system peptidase.
  • the prodrug is capable of crossing the BBB.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2 w-amino acid cleavage product (e.g., C2am-G ⁇ y), a C5 « -amino acid cleavage product (e.g., C5am- Gly), a C2fl7M-peptide cleavage product, a C5 ⁇ «-peptide cleavage product, or a combination thereof.
  • the proteolytic product is a combination of C2 ⁇ #z-Gly and C5 w-Gly. Suitable central nervous system peptidases and peptide sequences are described above.
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the ischemic tissue.
  • the subject is at risk of a first or subsequent ischemic event or requires a surgical procedure that increases the risk of ischemia-reperfusion injury.
  • ischemic event examples include individuals with known hypercholesterolemia, EKG changes associated with risk of ischemia, sedentary lifestyle, angiographic evidence of partial coronary artery obstruction, echocardio graphic evidence of myocardial damage, or any other evidence of a risk for a future or additional ischemic event (e.g., a myocardial ischemic event such as a myocardial infarction or a neurovascular ischemic event such as a cerebrovascular accident).
  • a myocardial ischemic event such as a myocardial infarction
  • neurovascular ischemic event such as a cerebrovascular accident
  • Risk factors for stroke that can demonstrate a subject's risk for ischemia of brain tissue include, without limitation, hypertension, cigarette smoking, carotid artery stenosis, physical inactivity, diabetes mellitus, hyperlipidemia, transient ischemic attack, atrial fibrillation, coronary artery disease, congestive heart failure, past myocardial infarction, left ventricular dysfunction with mural thrombus, and mitral stenosis. See, frigall, "Preventing ischemic stroke: current approaches to primary and secondary prevention," Postgrad. Med., 107(6):34-50 (2000). Further, complications of untreated infectious diarrhea in the elderly can include myocardial, renal, cerebrovascular, and intestinal ischemia.
  • subjects could be selected based on risk factors for ischemic bowel, kidney, or liver disease. For example, treatment would be initiated in elderly subjects at risk of hypotensive episodes (e.g., surgical blood loss). Other conditions that may result in ischemia include cerebral arterio venous malformation.
  • An at-risk subject can be selected by physical testing or eliciting the potential subject's medical history to determine whether the subject has any indications of risk for an ischemic event.
  • the subject selected for treatment is at risk of future ischemia, but has no present evidence of ischemia (e.g., crushing substernal chest pain or arm pain, shortness of breath, diaphoresis, etc.).
  • the amiloride conjugates of the present invention can also be administered prior to procedures in which ischemia may occur, e.g., prior to angioplasty or surgery such as coronary artery bypass graft surgery. As such, administration of the amiloride conjugates of the present invention is useful in preventing or reducing injury from ischemia-reperfusion in the heart, brain, liver, gut, kidney, bowel, or in any other tissue or organ.
  • the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the ischemic tissue peptidase.
  • the conjugate is a prodrug that releases an active (i.e., bioactive) proteolytic product upon selective cleavage by the ischemic tissue peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2 r ⁇ -amino acid cleavage product or a C2 ⁇ m ⁇ eptide cleavage product.
  • the proteolytic product is C2am-Gly.
  • the peptide is a substrate for an ischemic tissue peptidase such as, for example, an opioid neuropeptide peptidase (e.g., enkephalinase), a metalloproteinase (e.g., matrix metalloproteinase, disintegrin-metalloproteinase (ADAM)), a plasminogen activator, a cathepsin, a calpain, a caspase, or combinations thereof.
  • an opioid neuropeptide peptidase e.g., enkephalinase
  • a metalloproteinase e.g., matrix metalloproteinase, disintegrin-metalloproteinase (ADAM)
  • ADAM disintegrin-metalloproteinase
  • a plasminogen activator e.g., a plasminogen activator, a cathepsin, a calpain, a caspase, or combinations thereof.
  • the peptide is selected from the group consisting of Gly-Gly-Gly-Gly-Phe-Leu-OH, Tyr-D- Ala-Gly-Phe-Gly-NH 2 , Glu-Ser-Leu-Ala-Tyr-Tyr-Thr-Ala-Gly-NH 2 , Arg-Ser-Leu-Ser-Arg- Leu-Tl ⁇ r-Ala-Gly-l ⁇ 2 , Glu-Ser-Leu-D-Ala-Tyr-Tyr-Thr-Ala-Gly-NH 2 , Arg-Ser-Leu-Ser- Arg-D-Leu-Thr-Ala-Gly-NH 2 , and Arg-Ser-Leu-Ser-Arg-Leu-Thr-Ala-Gly-Gly-NH 2 .
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subj ect prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the ischemic tissue.
  • the subject is at risk of a first or subsequent ischemic event or requires a surgical procedure that increases the risk of ischemia-reperfusion injury.
  • the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the ischemic tissue peptidase.
  • the conjugate is a prodrug that releases an active (i.e., bioactive) proteolytic product upon selective cleavage by the ischemic tissue peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C5 ⁇ -amino acid cleavage product or a C5 ⁇ -pe ⁇ tide cleavage product.
  • the proteolytic product is C5am-Gly. Suitable ischemic tissue peptidases and peptide sequences are described above.
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X ! and X 2 are peptides comprising m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than 1, and wherein the peptide contains a cleavage site recognized (t.e., selectively cleaved) by a peptidase in the ischemic tissue.
  • the subject is at risk of a first or subsequent ischemic event or requires a surgical procedure that increases the risk of ischemia-reperfusion injury.
  • the method further comprises co-admimstering to the subject an agent (e.g., peptidase) that activates the ischemic tissue peptidase.
  • the conjugate is a prodrug that releases an active (i.e., bioactive) proteolytic product upon selective cleavage by the ischemic tissue peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2,5 -amino acid cleavage product or a C2,5twz- ⁇ eptide cleavage product.
  • the proteolytic product is C2,5 ⁇ ?n-(Gly) 2 . Suitable ischemic tissue peptidases and peptide sequences are described above. [0119]
  • the present invention provides a method for preventing or reducing ischemia-reperfusion injury in a subject in need thereof, the method comprising: administering to the subject prior to the onset of ischemia a therapeutically effective amount of a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids and n is an integer greater than 1, and wherein the peptide contains a cleavage site recognized (i.e., selectively cleaved) by a peptidase in the ischemic tissue.
  • the subject is at risk of a first or subsequent ischemic event or requires a surgical procedure that increases the risk of ischemia-reperfusion injury.
  • the method further comprises co-administering to the subject an agent (e.g., peptidase) that activates the ischemic tissue peptidase.
  • the conjugate is a prodrug that releases an active (i. e., bioactive) proteolytic product upon selective cleavage by the ischemic tissue peptidase.
  • the proteolytic product is amiloride or any enzymatic cleavage product such as a C2 ⁇ -amino acid cleavage product (e.g., C2 m-Gly), a C5 ⁇ -amino acid cleavage product (e.g., C5 w-Gly), a C2 m-peptide cleavage product, a C5 ⁇ -peptide cleavage product, or a combination thereof.
  • the proteolytic product is a combination of C2 w-Gly and C5am-Gly. Suitable ischemic tissue peptidases and peptide sequences are described above.
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • Xi and X 2 are peptides comprising m and n independently selected amino acids, respectively; and m and n are independently selected integers greater than 1, and at least one of the peptides contains a cleavage site recognized by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • the present invention provides a kit for the treatment of a central nervous system disease or disorder, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the central nervous system; and (b) directions for use of the conjugate in the treatment of the central nervous system disease or disorder.
  • kits for the treatment of a central nervous system disease or disorder can further comprise a second container holding a co-administered peptidase inhibitor that does not cross the blood brain barrier (BBB) and directions for use of the conjugate and the co-administered peptidase inhibitor.
  • BBB blood brain barrier
  • co-administration of the peptidase inhibitor prevents the activation and/or degradation of the inactive amiloride conjugate prodrug prior to its crossing the BBB.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • i and X 2 are peptides comprising m and n independently selected amino acids, respectively; and m and n are independently selected integers greater than 1, and at least one of the peptides contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • the present invention provides a kit for the prevention or reduction of ischemia-reperfusion injury, the kit comprising: (a) a container holding a conjugate having the formula:
  • X is a peptide comprising n independently selected amino acids, n is an integer greater than 1, and the peptide contains a cleavage site recognized by a peptidase in the ischemic tissue; and (b) directions for use of the conjugate in the prevention or reduction of the ischemia-reperfusion injury.
  • kits for the prevention or reduction of ischemia- reperfusion injury can further comprise a second container holding a co-administered peptidase inhibitor and directions for use of the conjugate and the co-administered peptidase inhibitor.
  • the peptidase inhibitor inhibits the activation and/or degradation of the inactive amiloride conjugate prodrug prior to the onset of ischemia.
  • compositions Amiloride Amino Acid and Peptide Conjugates:
  • the present invention provides novel amino acid and peptide conjugates of amiloride that are effective NHEl and/or NCX inhibitors and display cytotoxic and/or anitproliferative effects on tumor cells such as glioma cells.
  • Table 1 presents selected inhibitors of NHEl and NCX as described in the literature and the novel amiloride conjugates of the present invention.
  • C2 ⁇ m-X conjugates wherein X is an amino acid or a peptide, are within the scope of the present invention.
  • the present invention provides a C2 ⁇ conjugate comprising the following structure:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the amino acid or peptide is conjugated to the C(2) position of amiloride via an amide bond.
  • X is a peptide comprising a combination of independently selected amino acids or a polymer of one amino acid as described above.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • the peptide is a poly-glycine peptide.
  • the amino acid or peptide is connected to the C(2) position of amiloride via a linker.
  • C5am-X conjugates wherein X is an amino acid or a peptide, are within the scope of the present invention.
  • the present invention provides a C5am conjugate comprising the following structure:
  • X is n independently selected amino acids and n is an integer greater than or equal to 1.
  • the amino acid or peptide is conjugated to the C(5) position of amiloride via an amine bond.
  • X is a peptide comprising a combination of independently selected amino acids or a polymer of one amino acid as described above.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • the peptide is a poly-glycine peptide.
  • the amino acid or peptide is connected to the C(5) position of amiloride via a linker.
  • C2,5 ⁇ -X ⁇ - X 2 conjugates wherein Xi and X 2 independently comprise at least one amino acid, are within the scope of the present invention.
  • the present invention provides a C2,5 ⁇ r ⁇ conjugate comprising the following structure:
  • Xi and X 2 are m and n independently selected amino acids, respectively, and m and n are independently selected integers greater than or equal to 1.
  • the Xi amino acid or peptide is conjugated to the C(2) position of amiloride via an amide bond and the X 2 amino acid or peptide is conjugated to the C(5) position of amiloride via an amine bond.
  • m and n are both greater than 1, Xj and X 2 are either identical or different peptides comprising a combination of independently selected amino acids or a polymer of one amino acid as described above.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • a peptidase such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • the peptide is a poly-glycine peptide.
  • the amino acid or peptide is connected to the C(2) and/or C(5) position of amiloride via a linker.
  • both Xi and X 2 are glycine residues and m and n are both 1 (i.e., C2,5 r ⁇ -(Gly) 2 ).
  • C2,5 ⁇ -(Gly) 2 is suitable for use as a pseudopeptide residue that is likely non-hydrolyzable by peptidases and which can be internally incorporated into peptides known to cross the blood brain barrier.
  • the following analogs of [Leu] 5 - enkephalin amide can be generated that incorporate C2,5 ⁇ w-(Gly) 2 into the peptide sequence: (1) Tyr-O y- -G v-Phe-Leu-NH 2 (see, Figure 11);(2) Tyr-Gly-G y- -G y-Gly-Phe-Leu- NH 2 ; and (3) Tyr-D-Ala-G/v- -G/ -Phe-DLeu-NH 2 , wherein Gly-am-Gly is a C2,5am- (Gly) conjugate.
  • Such peptides can be tested with purified enkephalinase and fresh brain homogenates to analyze peptide fragmentation by LC-MS.
  • X ⁇ and X 2 are peptides wherein the ammo-terminus of i is coupled to the carboxyl-terminus of X 2 by a peptide bond to form a cyclized C2,5am- peptide conjugate.
  • the cyclized C2,5 -peptide conjugate comprises from 9 to 14 amino acids (i.e., the sum of m and n is between 9 and 14).
  • the cyclized peptide would be biologically inactive and hydrophobic. However, endopeptidase cleavage of the X X 2 peptide linker would generate a linear, functional, hydrophilic molecule.
  • C2 ⁇ r ⁇ -Gly-Peptide-C5 ⁇ m-Gly (“C2-C5 dimer") shown in Table 1
  • C2 ⁇ -Amino Acid-C5 ⁇ and C2 ⁇ m-Peptide-C5 ⁇ m di ers are within the scope of the present invention.
  • the present invention provides a C2,5am dimer conjugate comprising the following structure:
  • X is n independently selected amino acids and n is an integer ranging from 1 to 50.
  • X is a peptide comprising a combination of independently . selected amino acids or a polymer of one amino acid as described above.
  • n is between 4 and 12.
  • the peptide is selectively cleaved by a peptidase, such as a brain-specific or tumor-specific peptidase, or an enzyme activated during tissue injury.
  • the peptide is a poly-glycine peptide.
  • the amino acid or peptide is connected to the C(2) position of one amiloride via one linker and to the C(5) position of another amiloride via another linker.
  • C2,2 ⁇ and 05,5am amino acid and peptide dimer conjugates are also within the scope of the present invention.
  • the C5am and Clam amino acid and peptide conjugates of the present invention are unique and have the following chemical properties that make them particularly useful therapeutic agents for the treatment of cancer (e.g., glioma, breast cancer), treatment of central nervous system disorders (e.g., traumatic brain injury, seizure), prevention or reduction of ischemia-reperfusion injury, etc. :
  • the C2am and C5 ⁇ w amino acid conjugates are more polar than other amiloride derivatives. Their hydrophilicity has facilitated aqueous solubilization and restricts their activity to ionic exchangers on the cell surface, thereby reducing general toxicity.
  • the C5 m-Gly conjugate inhibits NHEl at greater than 4 times the potency of amiloride in glioma cells, and the inhibition is rapidly reversed when the conjugate is removed from the bath (Palandoken et al, supra).
  • the C2 ⁇ -Gly conjugate kills glioma cells at greater than 50 times the potency of amiloride.
  • the C2 ⁇ and C5 amino acid conjugates are efficiently coupled to peptides that can be designed to contain cleavage sites recognized by brain-, tumor-, or ischemic tissue-specific peptidases. Cleavage of the peptide conjugates produces proteolytic products that can be considerably more polar than the parent conjugate.
  • combinatorial peptide chemistry can generate a large number of derivatives that can be screened to optimize glioma cytotoxicity and selectivity.
  • the C2,5 ⁇ w-(Gly) 2 conjugate i.e., 2,5-bis-glycine amiloride
  • BBB blood brain barrier
  • the C2,5 ⁇ -(Gly) 2 -peptide conjugate (i.e., Peptide 1-Gly- ⁇ -Gly-Peptide 2) can be made more hydrophobic by protecting any free carboxylic acid groups, e.g., with a protecting group. Enzymatic cleavage of Peptide 1 and/or Peptide 2 liberates the more hydrophilic, bifunctional molecule Gly- ⁇ m-Gly, capable of modulating the inhibition of both NHEl and NCX. f.
  • the C2-C5 dimeric amiloride conjugates can be coupled to each other through a peptide linkage that generates a hydrophobic, di-amide molecule.
  • Blocking C- temiinal carboxylates by amidation or methylation has been shown to facilitate access across the BBB.
  • the more hydrophilic C2 ⁇ m-Gly and C5 m- Gly can be released following cleavage of the internal peptide linkage from a hydrophobic C2-C5 dimeric amiloride glycine conjugate by brain-, tumor-, or ischemic tissue-specific peptidases.
  • the present invention provides methods for administering hydrophobic peptide-drug conjugates that can then be converted in vivo to hydrophilic agents upon the action of a peptidase. These methods permit efficient accessibility and penetration of the conjugates into a tissue (e.g., ischemic tissue) or other site of action (e.g., across the blood brain barrier) and utilize peptidases present in the tissue or site of action to selectively cleave the conjugate and liberate a hydrophilic agent that acts at the level of the cell surface, thereby reducing general toxicity.
  • tissue e.g., ischemic tissue
  • other site of action e.g., across the blood brain barrier
  • Suitable drugs for use in the peptide-drug conjugates include, without limitation, anti-cancer agents, anti-inflammatory agents, anti- viral agents, antifungal agents, and anti-bacterial agents, wherein the peptide conjugated to the drug is selectively cleaved by a peptidase expressed at the intended site of drug action, e.g., a tumor, an injured tissue, an organ, etc., to generate the hydrophilic agent.
  • amiloride conjugates of the present invention can be provided in pharmaceutical compositions for administration to a subject in need thereof.
  • Such compositions will contain, in addition to at least one amiloride conjugate as the active agent(s), one or more pharmaceutically acceptable excipients, carriers, diluents, tissue permeation enhancers, solubilizers, and adjuvants.
  • Other therapeutic agents may be included, e.g., anticancer agents, vasoconstrictors, anti-inflammatory agents, antibiotics, and counter- irritants.
  • Suitable anticancer agents include, but are not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, interferons, radiopharmaceuticals, and conjugates of peptides with anti-tumor activity, e.g, TNF- ⁇ .
  • the compositions may be formulated using conventional techniques such as those described in Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17 th Ed. (1985) and "Modem Pharmaceutics," Marcel Dekker, Inc. 3 rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).
  • compositions of the present invention comprising amiloride conjugates can be in the form of emulsions, creams, jelly, solutions, and ointments.
  • compositions can be in the form of sterile injectable solutions and sterile packaged powders.
  • injectable solutions are formulated at a pH of about 4.5 to about 7.5.
  • compositions can be in the form of tablets, capsules, emulsions, suspensions, solutions, syrups, sprays, and lozenges.
  • suitable excipients include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline, syrup, and methylcellulose.
  • compositions can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents, emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates, sweetening agents, and flavoring agents.
  • lubricating agents such as talc, magnesium stearate, and mineral oil
  • wetting agents such as talc, magnesium stearate, and mineral oil
  • emulsifying and suspending agents such as methyl- and propylhydroxy-benzoates, sweetening agents, and flavoring agents.
  • preserving agents such as methyl- and propylhydroxy-benzoates, sweetening agents, and flavoring agents.
  • sweetening agents such as talc, magnesium stearate, and mineral oil
  • preserving agents such as methyl- and propylhydroxy-benzoates, sweetening agents, and flavoring agents.
  • the compositions may also comprise biodegradable polymer beads and dextran and cyclodextrin
  • the C5 ⁇ m and C2 ⁇ m peptide conjugates of the present invention are selectively cleaved within the brain by an opioid neuropeptide peptidase (e.g., enkephalinase), a metalloproteinase (e.g., matrix metalloproteinase, disintegrin- metalloproteinase (ADAM)), a plasminogen activator, a catheps n, a calpain, a caspase, or combinations thereof.
  • opioid neuropeptide peptidase e.g., enkephalinase
  • a metalloproteinase e.g., matrix metalloproteinase, disintegrin- metalloproteinase (ADAM)
  • a plasminogen activator e.g., a catheps n, a calpain, a caspase, or combinations thereof.
  • peptides are designed to identify the minimum number of amino acid residue
  • enzymatic recognition sequences are designed within the peptides to permit selective cleavage by enzymes (e.g., brain and/or tumor peptidases).
  • enzymes e.g., brain and/or tumor peptidases.
  • C5 ⁇ r ⁇ -Gly or C2 ⁇ r ⁇ -Gly conjugates containing peptides that mimic opioid peptides or MMP-2 substrates attached to the glycine are within the scope of the present invention.
  • conjugates can be evaluated for any of various structure-activity relationships (SAR) such as enzymatic specificity and biological activitiy in glioma cells.
  • SAR structure-activity relationships
  • the C5 ⁇ m-Gly or C2 -Gly conjugates are coupled to [Leu] 5 -enkephalin analogs (e.g., Gly-Gly-Gly-Gly-Phe-Leu-OH) that closely resemble members of the opioid peptide family that effectively enter the brain following intravenous injection (Cornford et ⁇ , Lancet Neuro , 1 :306-315 (2002)).
  • Any of the peptide conjugates of the present invention are useful for enhancing the efficacy and selectivity (i.e., specificity) of the antiproliferative and cytotoxic effects of amiloride conjugates in killing and/or inhibiting the proliferation of tumor cells such as glioma cells.
  • Recognition sequences within the conjugates are designed to be cleaved by brain or tumor peptidases to increase the hydrophilicities of the active compounds to impede their intracellular permeation, thereby reducing toxicity.
  • the C2am-Gly, C5am-Gly, and peptide conjugates thereof are synthesized with high overall yields.
  • the conjugates demonstrate cytotoxic and/or antiproliferative effects on U87 glioma cells that correspond with their predicted inhibition of NCX and NHEl.
  • solubilization is a common problem with peptides
  • the peptide conjugates of the present invention are soluble in mixtures of aqueous buffers containing approximately ⁇ 20% of DMSO.
  • peptide derivatives frequently need modified amino acid residues in order to be clinically effective and/or to prevent unwanted cleavage by endogenous peptidases
  • D-amino acids N-methyl amino acids, N-substituted glycines, cyclic amino acid derivatives, and combinations thereof may be introduced into the peptide conjugates of the present invention.
  • peptidomimetism introduces hydrocarbon bonds that retain the confomeric structure of the peptide backbones, while retaining critical amino acid sidechains to overcome problems of peptide instability, poor absorption, and rapid metabolism (Marshall, Biopolymers, 60:246-277 (2001)).
  • combinatorial peptide syntheses can rapidly generate novel sets of amiloride derivative compounds that can be examined to optimize efficacies using high throughput, tetrazolium-based screening assays of viable cell numbers of glioma cells and primary astrocytes.
  • a particularly appealing feature of the synthesis strategies of the present invention is the flexibility with which the peptide side chains can be incorporated onto the amiloride core. For example, partial or complete peptide sequences may be assembled prior to the reaction with resin-bound amiloride, as opposed to a step-wise amino acid sequence construction. This option provides the opportunity to incorporate radiolabels into the synthetic scheme by using radiolabeled peptide sequences. The incorporation of radiolabels could be particularly useful following preliminary LC-MS analyses to further assess the partitioning of compounds from the vascular compartment into brain tissue, their intracerebral efflux, and stability.
  • the endopeptidase subclass of peptidases (EC3.4) is divided into sub-subclasses on the basis of catalytic mechanism, and their specificity is used to identify individual enzymes within the groups. These are the sub-subclasses of serine endopeptidases (EC 3.4.21), cysteine endopeptidases (EC 3.4.22), aspartic endopeptidases (EC 3.4.23), metalloendopeptidases (EC 3.4.24), and threonine endopeptidases (EC 3.4.25). Endopeptidases that cannot be assigned to any of the sub-subclasses listed above are provided in sub-subclass EC 3.4.99.
  • the endopeptidases shown in Table 2 are activated by tissue injury, hypoxia- ischemia, and/or in infiltrative cancers, including grade ni and IV malignant gliomas. Any peptidase uniquely or selectively expressed by a tumor, tissue, or organ could provide a target for selective cleavage of an amiloride-peptide conjugate of the present invention.
  • Table 2 shows various known peptide substrates for: (1) peptidases activated by tissue injury or hypoxia-ischemia (e.g., heart and brain), such as calpains and caspases; and (2) peptidases activated by tumors (e.g., brain tumors), such as matrix metalloproteinases and urokinase plasminogen activators. Further, Table 2 shows amiloride-peptide conjugates that can be selectively cleaved with the specific peptidase(s). Table 2. Peptidases, Known Peptide Substrates, and Amiloride-Peptide Conjugates.
  • the peptide sequences in the amiloride-peptide conjugate are preferably designed to be resistant to digestive enzymes such as trypsin, chymotrypsin, elastase, and carboxypeptidases.
  • the conjugates are preferably resistant to plasma proteases such as those of the thrombolytic pathway (e.g., thrombin).
  • peptide derivatives frequently need modified amino acid residues in order to be clinically effective and/or to prevent unwanted cleavage by endogenous peptidases. Therefore, D-amino acids, N-methyl amino acids, N-substituted glycines, cyclic amino acid derivatives, and combinations thereof may be introduced into the amiloride-peptide conjugates of the present invention, and peptidomimetism can be used to overcome problems of peptide instability, poor absorption, and rapid metabolism (Marshall, supra).
  • an MMP-2-cleavable peptide linker can contain modified amino acid residues flanking the MMP-2 cleavage sequence in order to confer resistance to endogenous peptidases other than MMP-2.
  • C5 m-amino acid and peptide conjugates are particularly useful as highly selective and potent inhibitors of sodium-proton exchange (i.e., NHEl) whereas C2 ⁇ -amino acid and peptide conjugates are particularly useful as selective and potent inhibitors of sodium-calcium exchange (i.e., NCX).
  • C5am conjugates are particularly useful for reducing tissue swelling (e.g., acute brain swelling from stroke or head trauma) and C2 conjugates in conjuction with C5am conjugates are particularly useful for killing cancer cells that reside in hypoxic-ischemic environments and/or for serving as a neuroprotectant during stroke or cardiac ischemia by preventing sodium and calcium entry into cells via NHEl and NCX, respectively.
  • conjugates produced by peptide additions to both the C2 and C5 positions of amiloride are particularly useful because they would likely change the ratio of NCX/NHE1 inhibition and affect the selectivity for inhibiting the different transporter subtypes present in different tissues. This could be assessed using high throughput screens for each transporter.
  • amiloride conjugates of the present invention provide cytotoxic and/or antiproliferative effects by at least one of the following mechanisms: (1) reduction in intracellular pH (pHj); (2) impairment of glycolysis; and (3) increase in intracellular calcium levels ([Ca 2+ ]i). Such effects are mediated by inhibition of NHEl, NCX, a combination of NHEl and NCX, or through inhibition of other ionic transporters (e.g., other cell-surface Na + exchangers).
  • Figure 1 illustrates a model for amiloride conjugate-induced tumor cell death.
  • compositions of the present invention comprising an amiloride conjugate may be administered by any of the accepted modes of administration of agents having similar utilities, for example, by oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intraarterial, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini- osmotic pump, to a subject. Administration is by any route, including parenteral and fransmucosal (e.g., oral, nasal, vaginal, rectal, or transdermal).
  • parenteral and fransmucosal e.g., oral, nasal, vaginal, rectal, or transdermal.
  • Parenteral administration includes, e.g., intravenous, intramuscular, infra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • administration may be directly to the tumor and/or into tissues surrounding the tumor.
  • Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
  • compositions may be administered as a single injection or continuously through an indwelling catheter, or administered topically to the skin, mucus membranes, etc.
  • the composition containing the amiloride conjugate may be administered repeatedly, e.g., at least 2, 3, 4, 5, 6, 7, 8, or more times, or the composition may be administered by continuous infusion.
  • compositions can be formulated in a unit dosage form.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired onset, tolerability, and therapeutic effects, in association with a suitable pharmaceutical excipient (e.g., an ampule).
  • a suitable pharmaceutical excipient e.g., an ampule
  • more concentrated compositions may be prepared, from which the more dilute unit dosage compositions may then be produced.
  • the more concentrated compositions thus will contain substantially more than, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times the amount of the amiloride conjugate.
  • compositions of the present invention can also be provided in a lyophilized form.
  • Such compositions may include a buffer, e.g., bicarbonate, for reconstitution prior to administration, or the buffer may be included in the lyophilized composition for reconstitution with, e.g., water.
  • the lyophilized composition may further comprise a suitable vasoconstrictor, e.g., epinephrine.
  • the lyophilized composition is provided in a syringe, optionally packaged in combination with the buffer for reconstitution, such that the reconstituted anesthetic composition can be immediately administered to a patient.
  • the dose administered will vary depending on a number of factors, including, but not limited to, the type of cancer or ischemic tissue, the location of the tumor or ischemic tissue, and/or the physical condition of the patient. Preferably, the smallest dose and concentration required to produce the desired result should be used. Dosage should be appropriately adjusted for children, the elderly, debilitated patients, and patients with cardiac and/or liver disease. However, the reduced toxicity associated with the amiloride conjugates of the present invention permits a wider margin of safety for dosage concentrations and for repeated dosing.
  • the methods of the present inventon further comprise co- administering to the subject an agent (e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.) that activates an endogenous peptidase (e.g, a tumor-specific peptidase) which in turn selectively cleaves a peptide on the amiloride conjugate.
  • an agent e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.
  • an agent e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.
  • an agent e.g., small organic molecule, peptide, protein, polypeptide, peptidase, oligosaccharide, etc.
  • an endogenous peptidase e.g, a tumor-specific peptidas
  • agent or peptidase may occur either at the same time as the administration of the amiloride conjugate, or may be administered sequentially in a predetermined order.
  • the agent or peptidase is administered to a subject after the amiloride conjugate is administered.
  • the time of agent or peptidase administration following amiloride conjugate administration, or "intervention time,” is influenced by a number of factors, such as blood clearance rates and tumor uptake and clearance rates.
  • the intervention time is between 1 and 24 hours. More preferably, the intervention time is at about 6 hours.
  • the intervention time should be such that the agent or peptidase increases the release of an active (i.e., bioactive) proteolytic product from the conjugate relative to its release in the absence of the agent or peptidase.
  • the proteolytic product is amiloride ("am"), C2am-Gly, C5am-Gly, C2,5 ⁇ m-(Gly) , or combinations thereof.
  • NHEl inhibition reduced pHj in U87 glioma cells from 7.38 to 6.90.
  • Previous studies have demonstrated in C6 glioma cells that a modest pH, reduction impairs glycolysis and reduces intracellular levels of ATP (Erecinska et al, id; Silver et al, Glia, 21:35-45 (1997)).
  • ATP- and NADH-depletion has been shown to release calcium from intracellular stores in metabolically compromised asfrocytes (Chini et al, Biochem. J, 335:499-504 (1998); Wu et al , Glia, 21:315-326.
  • Eosin staining identified necrotic glioma cell death that was confined to poorly vascularized tumor regions.
  • Treated tumors, but not vehicle-treated controls contained glioma cells with damaged double-stranded, nuclear DNA that were identified using an antibody against H2Ax, a histone protein that binds to damaged double-stranded, nuclear DNA that can be produced by radiotherapy (Rogakou et al, J. Biol. Chem., 273:5858-5868 (1998)).
  • Table 3 Altered tumor doubling times following 5 days of amiloride or vehicle infusion. Doubline time # of # of R (gompertzian fit) day postimplant 10 12* 15* 17* animals measurements control 2.65 2.81 3.10 3.25 9 15 0.98915219 Vehicle pump 2.46 2.80 3.40 3.81 3 10 0.92141969 10mM amiloride reservoir 3.07 3.40 3.99 4.44 3 18 0.84935900 1Q0m amiloride reservoir 1.23 1.98 4.58+ 11.65++ 8 32 0.90521755 * drug infusion day 12-17; + statistically significant at P ⁇ 0.01 ++ statistically significant at P ⁇ 0.001
  • Glioma cells bordering regions of spontaneous necrosis in intracerebral C6 xenografts were found to survive, undergo cell cycle arrest, and appear to rely predominantly upon non-oxidative glycolysis (Gorin et al, Acta Neuropathol. 107:235-244 (2004)). Such glioma cells were also found to be scattered throughout the poorly vascularized tumor regions and continued to incorporate BrdU. Amiloride infusion killed glioma cells in poorly vascularized, hypoxic tumor environments that can be resistant to conventional chemotherapies and radiation therapy and are therefore prone to recurrence. As such, the elevated level of [Ca ]i caused by increased NHEl activity in these poorly vascularized glioma cells increases their susceptibility to pharmacological inhibitors of NCX and NHE 1.
  • Figure 5C shows that intrathecal infusion of amiloride in rats did not affect memory in a spatial learning task. Rats were subjected to a "probe" trial following the last acquisition trial in MWM assessment following tumor and drug administration. The hidden platform was removed and the rat was allowed to swim for 60 seconds. The duration of time spent in the "target" quadrant (formerly containing the platform) was recorded.
  • the dashed line indicates chance performance at 15 seconds. Both groups of rats demonstrated memory for the position of the hidden platform by increased time spent in the target quadrant. There was no significant difference in performance between amiloride and vehicle groups. Thus, amiloride infused at 276 pmol/24h was associated with modest impairment of spatial learning and with occasional seizures, but no demonstrable neuropathology.
  • DCB was associated with 4 of 5 animals dying during the following 12 to 24h.
  • DCB is fluorescent ( ⁇ e X 382nm, ⁇ e m 416nm), and confocal microscopy with 0.8 ⁇ m optical sections demonstrated that the hydrophobic DCB enters glioma cells and primary asfrocytes withinl50 minutes and associates with the endoplasmic reticulum (ER). Rapid cell permeation and association with the ER was also observed with ethylisopropylamiloride
  • EIPA an NHEl inhibitor that is also toxic to many cell types.
  • DCB and EIPA likely contribute to their general cellular toxicity (Palandoken et al, supra).
  • a glycine was conjugated to the C(2) guanidine sidechain of amiloride (see, Scheme 2, compound 5) by reaction of Boc-protected glycine (4) with isobutylchloroformate followed by treatment with amiloride.
  • Conjugate 5 was obtained as a hydrochloride salt in 57% overall yield after HCl-mediated deprotection, and was purified by recrystallization. Mass and spectral analyses confirmed the structure. ' -HCl Scheme 2
  • C(5)-amiloride glycine conjugate (C5 ⁇ »t-Gly) inhibits NHEl in U87 glioma cells and is antiproliferative.
  • spectrofluorometric measurements demonstrated that ⁇ 10 ⁇ M C5 ⁇ -Gly (Scheme 1, compound 3a) inhibited NHEl in gliomas.
  • Manual cell counts with trypan blue demonstrated that C5 ⁇ -Gly at ⁇ 100 ⁇ M inhibited the proliferation of U87 glioma cells to 22% of stage-matched controls by 48h.
  • C5 -Gly kills glioma cells.
  • C2 ⁇ -Gly (Scheme 2, compound 5) killed U87 glioma cells at ⁇ 10 ⁇ M concentration within 24h, as compared to amiloride (500 ⁇ M) and DCB (15 ⁇ M). Morphologically, dying cells appeared swollen with pyknotic nuclei consistent with necrosis.
  • C2 m-Gly increased [Ca 2+ ]j in U87 glioma cells, analogous to the effects of DCB or high doses of amiloride. Further, C2 ⁇ r ⁇ -Gly is more polar than DCB and was not visualized entering the glioma cells by confocal microscopy after 90-240 minutes.
  • Log dose screening of C2 ⁇ -Gly using the MTT assay in a panel of 5 glioma cells and primary asfrocytes was performed, followed by assessment of its antiproliferative and cytotoxic effects using manual cell counts coupled with frypan blue and its ability to inhibit colony formation.
  • This example shows the results of enzyme degradation assays performed on the C5 ⁇ -Gly conjugates from Example 4 (see, Scheme 1, compounds 3a-c).
  • Compound 3b is a C5 ⁇ w-Gly-peptide conjugate containing two D-amino acids
  • compound 3c is a C5am- Gly-peptide conjugate coupled to a peptide to generate an analog of opioid peptides that cross the blood brain barrier (BBB).
  • BBB blood brain barrier
  • the resultant conjugates (compounds 3a-c) were tested for selective cleavage by the brain peptidase enkephalinase (neutral endopeptidase 24.11; Calbiochem) via incubation for 24h in the presence or absence of the enzyme, and aliquots from the reaction solutions were then analyzed by LC-MS to identify the C5 -Gly conjugate (compound 3a), starting material, and enzymatic cleavage products (see, Scheme 3).
  • the conjugates were analyzed following treatment with (1) bovine pancreatic trypsin (Calbiochem) or (2) the buffer solutions without enzymes.
  • Compound 3c (C5 ⁇ m-Gly-Gly-Gly-Gly-Phe-Leu- OH) was designed to be a peptide analog of the Leu-enkephalin family of peptides and was selectively cleaved by enkephalinase, generating the predicted C5 m-Gly cleavage product. However, as a negative control, treatment of compound 3c with trypsin did not generate C5 ⁇ w-Gly.
  • C(5) ⁇ r ⁇ -Gly (compound 3 a) is considerably more hydrophilic than most amiloride derivatives, a property that restricts its activity to the cell surface (e.g., less toxicity).
  • C(5)am-Gly can also be coupled to more hydrophobic peptides, such as a Leu- enkephalin peptide, that are transported across the BBB into the brain (e.g., greater accessibility).
  • Example 8 Amiloride-Peptide Conjugates as Prodrugs for NHE Inhibition During Ischemic-Reperfusion Injury.
  • amiloride-peptide conjugates with peptidase cleavage sites are biologically inactive NHE inhibitor prodrugs that can be administered prior to the onset of ischemia and subsequently activated by peptidases selectively expressed by the ischemic tissue for preventing or reducing ischemia-reperfusion injury.
  • a shift from oxidative to non-oxidative glycolysis causes increased intracellular acidosis in the cells of the ischemic tissue. This reduction in pH activates NHE, which increases [Na + ]i levels (see, Figure 7) (Orlowski et al, J. Biol. Chem., 272:22373-22376 (1997)).
  • NHE inhibitors such as cariporide are effective in preventing cellular damage resulting from cerebral and myocardial ischemia when administered prior to the ischemic event (Klein et al, Circulation, 92:912-917 (1995); Scholz et al, Cardiovasc. Res., 29:260-268 (1995); Gumina et ⁇ / " ., Circulation, 100:2519-2526 (1999), Suzuki et al, Brain Res., 945:242-248 (2002)).
  • NHE inhibitors such as cariporide
  • inactive NHE inhibitor prodrugs when administered prior to the onset of ischemia, cellular endopeptidases that are activated during the early stages of ischemia (see, e.g., Denault et al, Chem. Rev., 102:4489-4500 (2002)) can selectively cleave the inactive prodrugs to yield potent NHE inhibitors. Activation of the prodrugs by peptidases eliminates drug delivery concerns, while NHE inhibition is highly specific, low in toxicity, and occurs immediately subsequent to the ischemic event.
  • Figure 8 depicts the strategy for preventing or reducing ischemia-reperfusion injury using the NHE-inhibiting amiloride-peptide prodrugs of the present invention.
  • an inactive amiloride-peptide prodrug e.g., a C(5) ⁇ 7n-peptide conjugate
  • a subject in need thereof e.g., a subject at risk for an ischemic event
  • the synthesis and secretion of peptidases by an ischemic cell selectively cleaves the amiloride-peptide conjugate and releases the active NHE inhibitor (e.g., C(5)am-Gly), which inhibits NHE on the ischemic cell surface and prevents or reduces the injury associated with ischemia- reperfusion.
  • the active NHE inhibitor e.g., C(5)am-Gly
  • This strategy offers two distinct advantages: (1) specific peptide sequences permit selective cleavage by peptidases for site-specific tissue activation of amiloride-peptide prodrugs; and (2) the hydrophilic nature of the active NHE inhibitor released from the amiloride-peptide prodrug deters intracellular permeation and limits the inhibitor's action to cell surface transporters.
  • the amiloride-peptide prodrugs are inactive prior to selective cleavage by a peptidase, weakly active prodrugs are also within the scope of the present invention.
  • Endopeptidase 24.11 (neutral, porcine kidney) and trypsin (bovine pancreas) were purchased from CalBiochem (San Diego, CA) and used as received. Enzymatic cleavage experiments using endopeptidase 24.11 were conducted at 25°C in apH 7.4 Tris buffer (150mM NaCl, 50mM Tris, 0.1% Triton X-100) as recommended by the manufacturer (see also, Barnes et al, J. Neurochem., 64:1826-1832 (1995), Gafford et al, Biochemistry, 22:3265-3271 (1983)).
  • trypsin cleavage experiments were conducted at 25°C in pH 7.4 Dulbecco's phosphate buffered saline (Gibco; Grand Island, NY).
  • the digestion reactions included lO ⁇ M of the amiloride-peptide conjugate and 10 units of enzyme in 250 ⁇ L of buffer. Direct aliquots were analyzed by LC-MS/ESI following a 24 hour incubation period.
  • Fluorescence Microscopy Visualization of intracellular fluorescent amiloride conjugates was conducted using high-speed imaging, epifluorescent microscopy. Excitation light was provided by a xenon arc lamp coupled to the Polychrome IV scanning monochromator (Till Photonics; Grafelfing, Germany) that alternately excites with different wavelengths. Excitation light was delivered by fiber optics to cells through the epifluorescence port of a Nikon E600 microscope coupled to a Nikon Fluor 60X water immersion lens. The detector was an Orca H-ER CCD digital camera (Hamamatsu USA; Bridgewater, NJ), which is controlled by C-Imaging Simple PCI software (Compix; Cranberry Township, PA).
  • Intracellular emission intensities were collected in regions of interest (ROI) from an average of 4-8 cells/field using Simple PCI imaging software. Emission intensities were subtracted from mean intracellular intensities measured in glioma cells prior to the addition of the fluorescent amiloride conjugates. Statistical significance at PO.05 andPO.01 levels between compound 3a, amiloride, and EIPA were evaluated nonparametrically using the Wilcoxon rank sum test (Sigma Statview v.3.0; Jandel Scientific; San Rafael, CA) as described in Vali et al, J. Cell Physiol, 185:184-199 (2000). Images were captured as TIFF files (C-imaging Simple PCI software), and light and fluorescent images of the same field were imported in Photoshop 6.0 and vector graphics added using Illustrator 9.0.1 (Adobe; San Jose, CA).
  • trypsin was employed as a negative control to ensure that any observed cleavage products could be ascribed only to endopeptidase-specific interactions (Jackson, Protein Science, 8:603-613 (1999)). Trypsin digestion did not cleave any of the amiloride conjugates with the exception of 3c (see, Table 5).
  • NHE inhibition by compounds 3a and 3c was evaluated using intracellular pH (pHj) measurements in the U87 human glial cell line (Hegde et al, supra). Cells loaded with BCECF were then acidified using the ammonium chloride pre-pulse method (Roos et al, Physiol Rev, 61:296-434 (1981)). The subsequent sodium-dependent recovery of pH by these cells in the absence of bicarbonate was monitored using a spectrofluorometer.
  • NHEl type 1 sodium proton exchanger
  • the IC 50 of amiloride depends upon external [Na] , and its value in U87 glial cells (50 ⁇ M) is modestly higher than those described in the UI 18 glial cell line (17 ⁇ M) and in primary rat asfrocytes (6 ⁇ M) (McLean et al., supra).
  • the IC50 of cariporide (74nM) is comparable to values published using CHO cell lines (30nM) (Kawamoto et al, Eur. J. Pharmacol, 420:1-8 (2001)).
  • Compound 3c did not inhibit NHEl in U87 glial cells and concentrations exceeding lOO ⁇ M produced interfering fluorescent background.
  • compound 3 a was at least 4-fold more potent than the parent compound, amiloride, but less active than the benzoylguanidine derivative, cariporide.
  • the inhibition of NHEl was rapidly reversed following the removal of compound 3 a, in contrast to the slow and incomplete recovery observed with amiloride and ethylisopropylamiloride (EIPA). This result indicated that intracellular permeation by the more hydrophilic compound 3 a differed significantly from that of the more hydrophobic amiloride and the C5am alkyl homolog EIPA.
  • EIPA, and compound 3 a could be visualized using fluorescent microscopy.
  • the relative molar absorptivity constants determined at 380nm excitation and 510nm emission for amiloride, EIPA, and compound 3a are 1, 2, and 13, respectively.
  • Compound 3a demonstrated significant intracellular fluorescence only in the rare dying and dead cells having increased membrane permeabilities. These dying and dead cells were identified by their co-staining with trypan blue, a visible dye that is excluded by viable cells ( Figures 5C and 5D; Hegde et al. , supra). The intracellular detection of compound 3a fluorescence only in trypan blue positive (i.e., dead) cells further verified that the conjugate remains excluded from viable U87 cells after 180 minutes, relative to amiloride and EIPA.
  • NHE sodium-proton
  • NCX sodium-calcium
  • the novel strategy of using the amiloride-peptide conjugates described herein as inactive prodrugs that can be enzymatically activated to generate inhibitors of NHE overcomes the limitations of current therapies for ischemia-reperfusion cytotoxicity.
  • the amiloride-peptide conjugate prodrugs are capable of residing in tissues prior to the onset of ischemia. Peptidases generated during the early phases of ischemia then selectively cleave the inactive prodrug and unmask an active NHE inhibitor molecule.
  • Compound 3b was designed as a negative control as it contains two D- amino acids in the peptide sequence instead of a Gly-Gly motif to ensure resistance to enkephalinase-mediated cleavage.
  • Enzyme-mediated cleavage of compound 3d was designed to generate compound 3 a, provided that the amiloride substitution for ⁇ Tyr] does not alter the Gly-Gly recognition by enkephalinase.
  • compound 3a (-6.23, calculated) indicate a substantial difference in hydrophilicity), which also predicts that compound 3a would be less likely to permeate cells, unlike amiloride or EIPA (Kraut et al, Anal Biochem., 214:413-419 (1993)).
  • the intrinsic fluorescence of the amiloride conjugates permitted the use of a quantitative fluorescent microscopy system to detect their intracellular accumulation. Fluorescent microscopy failed to detect the intracellular accumulation of compound 3a after 180 minutes, in contrast to the rapid cell permeation observed with amiloride and EIPA (see, Figure 9) .
  • the permeation properties of the more polar compound 3 a restricts its activity to cell surface exchanger proteins while limiting non-specific intracellular toxicity, which have been observed with amiloride and EIPA.
  • peptide sequences that are substrates for endopeptidases specifically activated during the early stages of brain or heart ischemia-reperfusion injury can be conjugated to amiloride to generate inactive prodrugs.
  • the selective activation of an NHE inhibitor prodrug by glioma-specific endopeptidases assists with the regional treatment of intracellular edema associated with these aggressive intracerebral tumors (Gorin et al. , Acta Neuropathol, 107:235-244 (2004)) and produced during cerebral ischemia and traumatic brain injury.
  • the prodrug strategy described herein can be adapted to synthesize C2-amino acid and peptide amiloride conjugates, which demonstrate dual NHE and NCX inhibitory activities.
  • Such prodrugs can complement the C5-amino acid and peptide amiloride conjugates to even more effectively limit ischemia-reperfusion tissue damage.
  • Example 9 Identification of the Cellular Mechanisms by which Inhibition of NCX and NHEl, Respectively, Produce Glioma Cell Death and Inhibit Proliferation.
  • Experiment #1 Determine whether amiloride derivatives that inhibit Na + - dependent Ca 2+ efflux kill glioma cells primarily by increasing [Ca 2+ ], to cytotoxic levels.
  • cells can be loaded with fura-2FF and imaged using a multi-wavelength inverted fluorescent microscope equipped with a quantitative high speed imaging system as previously described (Nali et al, J. Cell Physiol, 185:184-99 (2000)).
  • the effect of ionomycin on [Ca 2+ ]i can be compared with that produced by the ⁇ CX inhibitors DCB and C2 -Gly.
  • the dose-dependent inhibition of ⁇ CX by DCB and C2 ⁇ w-Gly in U87 gliomas can also be measured.
  • the relative IC 5 o values of these compounds can be compared with those of cariporide and C5 ⁇ n-Gly.
  • Cariporide is a selective inhibitor of ⁇ HE1 and C5 ⁇ m-Gly is predicted to inhibit ⁇ HE1» ⁇ CX.
  • the dose-dependent inhibition of NCX can be determined in a specfrofluorometer using glioma cells containing fura-2FF. Briefly, cells on coverslips are perfused with sodium-free buffer where non-permeable, N-methyl D- glucamine (NMDG) is used to replace external sodium.
  • NMDG N-methyl D- glucamine
  • the morphological similarity between glioma cell death produced by high dose amiloride, DCB, C2 -Gly, and ionomycin can be determined using manual cell counts coupled with Sytox Green.
  • Sytox Green a stain which binds to cytoplasmic and nuclear nucleic acids, is used to assess morphological changes associated with apoptosis and necrosis (Bien et al, J. Neurotra ma, 16:153-163 (1999)).
  • Manual cell counts with trypan blue can be employed to quantify the amount of glioma cell death produced by ionomycin and the amiloride derivatives at 24, 48, and 72 h.
  • Morphological changes associated with cell death can be examined by staining with Sytox Green.
  • the type of cell death produced by the amiloride derivatives can then be compared with the predominantly caspase-independent, morphologically necrotic cell death observed with amiloride.
  • a shared cell death mechanism increases the likelihood that the amiloride derivatives are killing glioma cells through common cellular mechanisms.
  • treated glioma cells can be pre-incubated with the pan-caspase inhibitor z-Val-Ala-Asp-fluoromethyl ketone (zNAD.frnk) or with calpeptin, a cell permeable inhibitor of ⁇ -calpain and mu-calpain activation.
  • zNAD.fmk-treated and calpeptin-treated cells can be compared with stage- matched cells treated with either a caspase negative control peptide (zFA.fmk) or a calpeptin negative peptide control ( ⁇ ovagen Cat. No. 208902).
  • the ratio of the two lOmM EGTA buffers can be adjusted, based on temperature, pH, and ionic strength to yield known concentrations of [Ca 2+ ] ex t.
  • the reduction of levels of [Ca 2+ ]i can be measured in glioma cells containing fura-2 using quantitative fluorescent microscopy.
  • the depletion of cytosolic free calcium by NCX can be adjusted by manipulating [Ca 2+ ] ex t or by isotonically increasing [Na + ] 0 .
  • amiloride >500 ⁇ M
  • DCB >20 ⁇ M
  • C2 ⁇ m-Gly ⁇ 10 ⁇ M
  • NHEl inhibitors including cariporide (80 ⁇ M) and amiloride (20 ⁇ M)
  • cariporide 80 ⁇ M
  • amiloride 20 ⁇ M
  • Calcium is highly buffered by subcellular organelles so that it is important to measure [Ca 2+ ]j in cells.
  • Experiment #2 Determine whether inhibition of sodium-mediated calcium efflux (i.e., the forward mode of NCX) is sufficient to cause glioma cell death.
  • SEA0400 is a selective inhibitor of NCX without any NHEl inhibitory activity (Matsuda et al, J. Pharmacol. Exp. Ther., 298:249-56 (2001)). Whether SEA0400 has cytotoxic and anti-proliferative effects on glioma cells can be determined.
  • Experimental Design A log dose screening of SEA0400 on a panel of 5 glioma cells and asfrocytes with the MTT assay can be performed and the presence of a reduction in the number of viable glioma cells compared with stage-matched, vehicle-treated control cells can be determined.
  • Concentrations of SEA0400 based upon the log dose screen can be selected and manual cell counts coupled with trypan blue can be employed to determine whether SEA400 has antiproliferative and cytotoxic effects.
  • U87 glioma cells can be loaded with fura-2FF treated with SEA0400 and the time course and magnitude of [Ca 2+ ]j can be measured using quantitative fluorescent microscopy. Changes in cell viability, proliferation, and [Ca 2+ ]j levels produced by SEA0400 can be compared to those produced by DCB and the C2 ⁇ -Gly and C5 r ⁇ -Gly conjugates.
  • SEA0400 kills glioma cells by a calcium-dependent mechanism can then be determined. Cytosolic calcium can be depleted in U87 glioma cells in a low calcium medium buffered isotonically with CaEGT A/K 2 EGT A. The cytotoxicity of SEA0400 can be compared to treated cells in control medium. Whether glioma cells treated with SEA0400 have altered their ability to form colonies compared with vehicle-treated, stage-matched controls can also be examined.
  • Experiment #3 Determine whether NHEl inhibition augments the glioma cytotoxicity associated with NCX inhibition.
  • the antiproliferative and cytotoxic effects of SEA0400 at pH ext 6.6 with SEA0400 in control medium can then be determined using manual cell counts coupled with trypan blue. As indicated by manual cell counts, the colony forming ability of glioma cells treated with SEA0400 compared to vehicle-treated, stage-matched controls can be examined. As cariporide could have additional unknown pharmacological effects, a direct reduction of pH; in glioma cells to a pH of 6.9 can be performed by acidifying the medium, and the effects of such direct intracellular acidification can be compared to those produced by cariporide. The cytotoxicity of SEA0400 with acidified cells can also be compared to that of SEA0400 confrol cells.
  • Experiment #4 Determine whether NHEl inhibition is associated with calcium mobilization from intracellular stores.
  • U87glioma cells with either impaired glycolysis or impaired oxidative phosphorylation can be studied. Glycolysis can be inhibited by culturing the glioma cells for 12 h in DMEM-HEPES medium, pH 7.4, where glucose has been replaced with 2-deoxyglucose (Wu et al, Glia, 21 :315-326 (1997); Donoso et al, J. Physiol, 448:493-509 (1992)).
  • oxidative metabolism in U87 glioma cells can be inhibited at either complex I, e.g., with roteonone, or complex UI, e.g., with antimycin.
  • Complex I e.g., with roteonone
  • complex UI e.g., with antimycin.
  • Cellular levels of ATP, ADP, AMP, and P can be measured in these metabolically compromised glioma cells in the presence or absence of cariporide, SEA0400, and a combination of both drugs.
  • the pHj can be measured in glioma cells loaded with BCECF, while [Ca 2+ ]i levels can be determined in cells loaded with fura- 2FFAM.
  • Changes in ATP, ADP, AMP, and Pj and in pH; and [Ca 2+ ]i can be measured at 0, 6, 12, 24, and 48 h in the freated glioma cells and compared with stage-matched, vehicle-treated controls.
  • the effects produced by cariporide can be compared to those produced by glioma cells maintained in acidified medium at pHe xt 6.6.
  • the metabolic and ionic effects produced by cariporide and by SEA0400 can be compared to those produced by DCB, C2am- Gly, C5 m-Gly, and peptide conjugates of C2 ⁇ r ⁇ -Gly and C5 m-Gly.
  • IP 3 inositol 1 ,4,5-triphosphoate
  • ER endoplasmic reticulum
  • impaired glycolysis can depress the ratio of NADH/NAD and lead to the generation of cyclic adenosine diphosphate ribose (cADPR) and nictotinic acid dinucleotide phosphate (NAADP).
  • cADPR and NAADP have been shown to enhance the calcium release from different ER-associated pools.
  • fransmitochondrial membrane potential ( m ) can be measured in metabolically manipulated cells that demonstrate increased [Ca 2+ ], levels.
  • Quantitative fluorescent microscopy can measure changes in m in glioma cells with the dye rhod-2.
  • Changes in m can be compared with ⁇ m in glioma cells treated with oligomycin or FCCP.
  • ATP can be quantitated with either luciferase (e.g., determination of cytosolic free ATP) or HPLC (e.g., determination of both ATP and ADP pools that are closely associated with the mitochondria) (Manfredi et ⁇ l, Methods, 26:317-326 (2002)).
  • luciferase e.g., determination of cytosolic free ATP
  • HPLC e.g., determination of both ATP and ADP pools that are closely associated with the mitochondria
  • [0224] Cell culture The five human glioma cell lines can be obtained from the American Tissue Culture Collection (ATCC). Primary cultures of rat asfrocytes can be isolated from the cerebral cortex of neonatal rats (0-1 day old). For measurements of [H + ]j, [Ca 2+ ];, and [Na + ]j, cells can be grown on glass coverslips coated with rat tail collagen type I.
  • ATCC American Tissue Culture Collection
  • MTT assay MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced from a tetrazolium salt to an insoluble purple formazon in viable cells that is detected spectrophotometrically (Mosmann, J. Immunol Methods, 65:55-63 (1983)). Absorbances can be measured at 570 nm using a Power Wave microtiter plate reader and KC Junior 340 vl.l 1 software. Mean background absorbances of cell-free media (630 nm) can be subtracted from these values.
  • lO ⁇ L aliquots of the suspension can be plated on a hemocytometer, and cells can be counted 5 minutes after staining. Simultaneous staining of cells with trypan (TB) and Sytox Green (SG) can be visualized by switching between visible light and fluorescein green.
  • Clonogenic assay Cells can be trypsinized and about 10 cells are plated on 100mm dishes and incubated for up to 14 days. Control U87 glioma cells have a plating efficiency of about 35% to about 45%. The plates can be stained with crystal violet and colonies can be counted (Pollack et al, Clin. Cancer Res., 7:1362-1369 (2001)).
  • pHj Spectrofluorometric measurements of intracellular pH. pHj can be measured using the fluorescent ratio dye 2',7'-bis(carboxyethyl)-5,6-carboxyfluorescein acetoxy-methyl ester (BCECF- AM), as described in McLean et al, supra. Briefly, cells on coverslips can be loaded for 30 min with 0.5 to 1.5 ⁇ M of BCECF-AM in HEPES -buffered Ringer's (HR) at 37°C, 0% CO 2 . Coverslips can be rinsed 3 times in HR, incubated in HR for 30 min at 37°C, 0% CO 2 , and then transferred to cuvettes that permit continuous perfusion of solution.
  • BCECF-AM fluorescent ratio dye 2',7'-bis(carboxyethyl)-5,6-carboxyfluorescein acetoxy-methyl ester
  • Calibration of BCECF can be performed using high K + solutions of known extracellular pH in conjunction with lO ⁇ M nigericin. Complete calibration curves can be constructed over the pH range of 6.2 to 8.2, with the ratio normalized to the ratio measured at either pH 7.0 (asfrocytes) or 7.4 (gliomas). A single calibration point can then be measured at the end of each experiment.
  • [0229] Spectrofluorometric measurements of intracellular calcium.
  • [Ca 2+ ]i can be measured by loading cells on coverslips for 60 min with 0.5 to 2.0 ⁇ M of fura-2AM or fura- 2FFAM in HEPES-buffered Ringer's (HR), 0% CO 2 , as described in Nali et al, supra.
  • Spectra can be excited at 340 and 380 nm with emission at 505nm.
  • Complete calibration curves can be constructed over the [Ca 2+ ]i range of between l ⁇ M to 100 ⁇ M using ionomycin with CaEDTA standards generated by the pH-metric method.
  • This method utilizes spectrofluorometric measurements of [H + ]j as described above.
  • the ammonium chloride prepulse method can be used to acidify cells in the presence of HR that is sodium-substituted with ⁇ MDG. Perfusion of the acidified cells with HR that contains sodium causes activation of ⁇ HE1 that is inhibited in a concentration-dependent fashion as described in McLean et al, supra.
  • IC 50 drug determinations for NCX This method utilizes spectrofluorometric measurements of [Ca 2+ ]i as described above. Treatment of the cells with FCCP (lO ⁇ M) elevates [Ca 2+ ] ⁇ levels in the presence of HR that is sodium-substituted with NMDG. Perfusion of the cells with HR that contains sodium causes activation of the forward mode of NCX that is inhibited in a concentration-dependent fashion with NCX inhibitors (Kopper et al, id).
  • Quantitative fluorescent microscopy of pHj. pH can be measured in human U87 glioma cells grown on coverslips at approximately 50% cell densities.
  • Cells can be loaded with BCECF- AM as described above.
  • Excitation light can be delivered by fiber optics to cells through the epifluorescence port of a Nikon E600 microscope coupled to a Nikon Fluor 40X or 60X water immersion lens.
  • the detector can be an Orca II-ER CCD digital camera which is computer controlled by C-Imaging Simple PCI software. Bath temperature and solutions can be regulated by a PDMI-2 open perfusion chamber.
  • [Ca 2+ ]j levels can be measured in cells loaded with either fura-2A or fura-2FFAM under the conditions described above.
  • adenine nucleotides are separated on a 4.6mm x 150mm reverse-phase C18 ODS column (Dychrom) under isocratic conditions (3.5% acetonitrile, 2.3mM tetrabutylammonium hydrogen sulfate, 215mM dipotassium hydrogen phosphate) at a flow of l-1.3ml/min. Standard curves for purified samples of ATP, ADP, and AMP (Sigma) are made just prior to analysis of the extracts.
  • Example 10 Evaluation of Amiloride Amino Acid and Peptide Conjugates in Glioma Cell Lines and Astrocytes.
  • This example illustrates: (1) a comparison of the cytotoxic and the antiproliferative efficacies of C2 w-Gly and C5 ⁇ -Gly in a set of five human glioma cell lines and in primary astrocytes; (2) a correlation of the effects of the amiloride amino acid conjugates on glioma cells with their inhibition of the sodium-calcium exchanger (NCX) and of the sodium proton exchanger (NHEl); (3) a utilization of the structure-activity information to design and synthesize amiloride peptide conjugates; and (4) an evaluation of the biological activities of these amiloride peptide compounds in a set of glioma cell lines and in primary astrocytes. Compounds that are efficacious and selective for gliomas can be further evaluated using intracerebral glioma xenograft models.
  • amiloride amino acid and peptide conjugates of the present invention can be analyzed as follows: 1. Evaluation of both protected (e.g., t-butyl oxycarbonyl) and deprotected amiloride conjugates by screening in primary astrocytes and in a set of five glioma cells lines listed in Table 7. 2. Log dose screening of the compounds using the MTT assay to measure the number of live glioma cells and primary astrocytes in 96 well microtiter plates at 24, 48, and 72 h. 3. Manual cell counts coupled with the trypan blue exclusion assay using the most potent and selective compounds to assess cytotoxic and anti-proliferative effects in glioma cells and primary astrocytes. 4.
  • protected e.g., t-butyl oxycarbonyl
  • deprotected amiloride conjugates by screening in primary astrocytes and in a set of five glioma cells lines listed in Table 7. 2. Log dose screening of the compounds using the MTT assay to measure the number
  • Experiment #1 Determine whether C5 m peptide conjugates primarily inhibit NHEl and exhibit a predominantly antiproliferative effect on glioma cells. Further, determine whether these 05am peptide conjugates reduce intracellular edema by their reduction of [Na + ] ! .
  • 05am peptide conjugates can be prepared using the solution-phase synthesis strategy according to Scheme 1 from Example 4 and the solid-phase synthesis strategy according to Scheme 4, below.
  • compound 3a see, Scheme 1 can be used as the starting material to synthesize additional peptide conjugates (compound 7) as well as their benzyl (compound 8A) and carboxylate derivatives (compound 8B).
  • the solid-phase synthesis strategy can proceed as follows: compound 3a can be loaded onto the resin by reaction with activated carbonate Wang resin and diisopropylethylamine, according to a procedure developed for the loading of structurally analogous guanidine- containing substrates (Ghosh et al, J. Org.
  • Fmoc deprotection can be effected using 50% piperidine in DMF.
  • the terminal amino acids of peptide compound 7 can be attached as benzyl (Bn) ester derivatives.
  • Cleavage of the peptide conjugates from the resin can be accomplished by exposure to trifluoroacetic acid (TFA) (Sieber, Tetrahedron Lett., 28:6147-6150 (1987)) to produce the benzyl-terminated conjugates (8A).
  • TFA trifluoroacetic acid
  • the corresponding free carboxylic acid derivative (8B) can be prepared by exposure of compound 7 to H 2 and Pd(OAc) 2 in DMF.
  • the effect of increasing peptide chain length on glioma cell proliferation and cytotoxicity as compared to primary astrocytes can also be examined. This biological activity can then be compared to their ability to inhibit NHEl and/or NCX in U87 gliomas.
  • the peptide sequences (depicted 5' ⁇ 3') examined can be: (1) Gly-Gly- ⁇ m; (2) Gly-Gly-Gly- ⁇ m; (3) Gly-Gly-Gly-Gfy- m; (4) Gly-Gly-Gly-Gly-G y- ⁇ m; etc., wherein "Gly- ⁇ m" represents the amiloride-glycine conjugate core structure.
  • Such C5 -(Gly) n conjugates can be evaluated in cell lines and in assays measuring NHEl and NCX inhibition. Analyses of these peptide conjugates using LC-MS can determine whether these glycine derivatives are stable in culture medium.
  • a second set of 05 ⁇ m peptide conjugates is modeled on the enkephalin peptide analog, Tyr-D-Ala-Gly-Phe-NH 2 , which has been shown to enter the brain from the vascular compartment by utilizing several transport mechanisms (Hau et ⁇ l, J. Ph ⁇ rm. Sci., 91 :2140- 2149 (2002)).
  • the initial peptide sequences derived from the enkephalin peptide analog can be as follows: (1) Tyr-Gly- ⁇ m; (2) Tyr-Gly-Gly- ⁇ m; (3) Tyr-D-Ala-Gt> ⁇ m; (4) Tyr-Gly- G ⁇ y-Gly- ⁇ m; (5) Tyr-Gly-Gly-D-Ala-G y- ⁇ ; and (6) Tyr-D-Ala-Gly-Phe- Gly- ⁇ m, wherein "Gly- ⁇ m” represents the amiloride-glycine conjugate core structure.
  • This set of conjugates can be designed to be cleaved or be resistant to brain peptidases by the introduction of D- amino acids. As such, neutral endopeptidase 24.11 in brain would cleave the peptide moieties in the absence of D-amino acids and generate the C5 ⁇ -Gly.
  • a third set of 05am peptide conjugates can be designed to provide a substrate for matrix metalloproteinase-2 (MMP-2).
  • MMP-2 matrix metalloproteinase-2
  • An analysis of peptide sequences that can be selectively cleaved by MMP-2 or MMP-9 has been described in Chen et al , J. Biol. Chem. , 277:4485-4491 (2002).
  • MMP-2 or MMP-9 Although not all malignant glioma cells express MMP-2 or MMP-9, at least 3 of the 5 human glioma cell lines in Table 7 have been documented to overexpress MMP-2.
  • C5am conjugates containing an MMP-2 peptide substrate can be incubated with recombinant MMP-2 enzyme (Oncogene #PF023), followed by homogenates prepared from U87 glioma cell lines.
  • MMP-2 enzyme Oncogene #PF023
  • the following peptides can be conjugated to the glycine at the C(5) position based upon sequences known to be recognized by MMP-2 as compared to other MMP family members, and with other known brain endopeptidases (Chen et al, supra): (1) Glu-Ser-Leu-Ala-Tyr-Tyr-Thr-Ala-G y- ⁇ w; (2) Arg-Ser-Leu-Ser-Arg-Leu- Thr-Ala-G/ - ; (3) Glu-Ser-Leu-D-Ala-Tyr-Tyr-Thr-Ala-G/y am; (4) Arg-Ser-Leu-Ser- Arg-D-Le
  • Experiment #2 Determine whether C2 amino acid and peptide conjugates inhibit NCX more than NHEl and whether they are more cytotoxic to glioma cells.
  • C2 peptide conjugates i.e., guanidino-linked
  • C2 peptide conjugates can be prepared using the solid- phase synthesis strategy outlined below in Scheme 5.
  • the 5-chloro atom of commercially available ester 9 (Aldrich Chemical Company; Milwaukee, WI) can be readily displaced under basic conditions by reaction with amines.
  • ester 9 can be freated with a PMB-activated amino-resin (e.g., amrno-(4-methoxyphenyl)methyl polystyrene, Novabiochem) to obtain resin-loaded pyrazine-ester 10.
  • guanidine can transform the methyl ester into the corresponding guanidine 11.
  • dichloro compound 2 (see, Scheme 1) can be reacted with aminomethylated resin to directly produce 11. Guanidine acylation can be performed according to the protocol for the preparation of compound 5 (see, Scheme 2).
  • the peptide side chains can then be elaborated using the well- established Fmoc protocol for solid-phase peptide synthesis. After Fmoc deprotection, treatment of the resin-bound conjugates at this stage with trifluoroacetic acid can deliver conjugate 13B.
  • the corresponding N-benzyl series (13A) requires that the terminal amino acid of the peptide side chain be added as its N-benzyl derivative rather than the N-Fmoc counterpart. In this event, the subsequent TFA-mediated resin cleavage reaction delivers conjugate 13 A.
  • the peptide sequences examined can be: (1) am-Gly; (2) am-Gly-Gly; (3) am-Gly-Gly-Gly; (4) am-Gly-Gly-Gly- Gly; (5) ⁇ r ⁇ -G/y-Gly-Gly-Gly-Gly; (6) -G y-D-Ala-Gly; (7) ⁇ -G y-D-Ala-Gly-D-Ala- Gly; etc., wherein "am-Gly " represents the amiloride-glycine conjugate core structure. Analyses of these 02am peptide conjugates using LC-MS can determine whether these compounds are stable in culture medium or require the addition of protease inhibitors to the culture medium.
  • C2 ⁇ -phenylalanine (C2 ⁇ m-Phe) and C2 ⁇ w-serine (C2 ⁇ w-Ser) conjugates can be synthesized and examined for their effects on glioma cytotoxicity and proliferation.
  • C2 peptide conjugates containing Phe and Ser analogs such as 2,4-dichloro-Phe and O-benzyl serine
  • conjugates are similar in structure to the hydrophobic DCB, but represent more polar amiloride derivatives that can position their peptide side chains to overlap with the C(2) dichlorobenzyl group of DCB.
  • molecular modeling of C2 ⁇ m-(2,4-dichloro)-Phe illustrates how the C(2) peptide side chain may be used to position functionality while maintaining a close structural similarity to DCB (see, Figure 10).
  • the serine hydroxyl group affords the opportunity to position benzyl and 2,4-dichlorobenzyl groups in a manner that closely mimics the potent amiloride analogs benzamil and DCB.
  • Experiment #3 Determine the biological activities of C2,C5 ⁇ r ⁇ -Gly 2 on glioma cell proliferation and cell death and correlate these activities with its inhibitory effects on NCX and NHEl.
  • C2,C5 -Gly 2 can be used as a "pseudo-peptide residue" that is likely non- hydrolyzable by peptidases and which can be internally incorporated into peptides known to cross the blood brain barrier (see, Figure 11).
  • Experiment #4 Determine the biological activities of C2 w-Gly-(Peptide)-C5 w- Gly (i.e., C2-C5 dimer) on glioma cell proliferation and cell death and correlate these activities with its inhibitory effects on NCX and NHEl .
  • the dimeric C2 ⁇ -Gly-(Peptide)-C5 ⁇ -Gly conjugate can be designed to be bifunctional, capable of generating both C5 ⁇ w-Gly and C2c -Gly upon cleavage of the internal peptide linker by a peptidase.
  • the hydrophobic nature of the intact, di-amide peptide conjugate facilitates its transport across the BBB, wherein the more hydrophilic C5 /w-Gly and C2 -Gly conjugates are released following selective cleavage of the peptide linker by a brain- or tumor-specific peptidase, such as enkephalinase or MMP-2.
  • these dimeric conjugates provide increased specificity and accessibility, with decreased toxicity to non-targeted (e.g., non-tumor) cells.
  • LC-MS Liquid chromatography/mass spectrometry
  • the mass spectral analysis can be performed using a Thermo Finnigan LCQ fitted to an Electrospray (ESI) source and Ion Trap mass analyzer with an ABI 120A HPLC.
  • a C18 column (Vydac, 300 A, 250 X ImM) can be used for all analyses. Samples can be injected and a gradient HPLC run can be performed from 5% to 90% acetonitrile over 1 h with 0.1% aqueous formic acid as the secondary solvent. Samples can be sprayed at the flow rate of 1 OO ⁇ l/min.
  • enkephalinase neutral endopeptidase 24.1.1
  • MMP-2 matrix metalloproteinase-2
  • MMP-9 matrix metalloproteinase-9
  • Chymotrypsin which recognizes peptide sequences containing basic amino acid side chains, can be used as a negative confrol.
  • the enzymatic digests containing the peptides can be incubated in buffers and at conditions recommended by the manufacturers for 6-12 h.
  • LC-MS can be used to identify the principal mass peaks of the peptides in samples taken from the enzymatic hydrolysates and from buffers without the addition of enzymes.
  • Example 11 Evaluation of the C2am and C5am Amino Acid and Peptide Conjugates in Intracerebral Glioma Xenografts.
  • Experiment #1 Determine which amiloride conjugates of the present invention kills or impedes the proliferation of a population of glioma cells surviving in a hypoxic- ischemic tumor microenvironment.
  • Glioma cells in hypoxic-ischemic tumor environments lack extracellular CO 2 HCO 3 " and must rely entirely upon increased activity of NHEl to maintain an alkalotic pH,- (McLean et al, supra): Perinecrotic glioma cells in C6 and U87 xenografts survive and undergo cell cycle arrest while scattered glioma cells within poorly vascularized tumor regions continue to incorporate BrdU (Gorin et al, Acta Neuropathol. 107:235-244 (2004)). Glioma cells in this environment are frequently resistant to radiation therapy and conventional chemotherapy. However, their altered intracellular ionic composition may result in their susceptibility to inhibitors of NCX and NHEl, e.g., compounds of the present invention.
  • NMR nuclear magnetic resonance
  • Log dose screening of compounds using a set of five glioma cells lines see, Table 7
  • primary astrocytes can be empolyed to identify those amiloride amino acid and peptide conjugates that are efficacious in selectively killing and/or inhibiting glioma proliferation.
  • manual cell counts can assess drug-induced alterations in cell proliferation and viability.
  • the in vivo toxicity studies can employ single, daily intracerebral infusions of the candidate compound into Sprague-Dawley rats for 12 days.
  • the infused drug concentration can be based upon the cell line studies and adjusted for the low protein content of the cerebrospinal fluid, which is 0.2% that of serum.
  • Animals can be behaviorally assessed for toxicity.
  • brains can be removed at days 4, 6, 8, 10, and 12 and frozen to determine drug levels by LC-MS as performed with amiloride.
  • the behavioral assessment can be conducted as performed with amiloride.
  • U87 glioma cells can be stereotaxically implanted into the corpus striatum of athymic rats. Tumors can be permitted to grow to 40mm 3 volume based upon established growth rates and verified by NMR. Alzet pumps modified to accommodate NMR imaging and deliver a range of 1-350 pmol/24h of amiloride amino acid or peptide conjugates for up to 14 days can then be connected. Tumor growth rates for U87 gliomas can be determined with 1 H-NMR by serially measuring volumes over a 10-day period (4 doubling times of U87 tumor). Following spectroscopic measurements of tumor volumes, animals can be injected i.p.
  • Tumor volumes can be serially determined prior to and following drug administration using NMR. Brain drug levels can be measured using NMR.
  • cmpds estimated number of amiloride-based derivatives to be tested based upon screening.
  • a survival study can be performed in a human U87 glioma xenograft model.
  • the protocol follows that of drug suppression of an established xenograft tumor.
  • the efficacy of drug treatment is assessed by the survival rate of animals at each day post-implantation.
  • Based upon published survival studies of the U87 glioma xenograft model (Nagane et al, Cancer Res., 60:847-853 (2000)), about 10 nude rats per freatment group can be compared against sham- and vehicle-treated animals (see, Table 9).
  • High dose amiloride infusion for 12 days with the Alzet pump can demonstrate that levels in the brain peak at day 8 and are decreasing by day 12 (.see, Example 2).
  • the accumulation in the brain indicates the possibility that pulsed administration of amiloride or its amino acid or peptide conjugates could be more efficacious and have less-side effects.
  • LC-MS can be used to measure the levels of the amiloride amino acid and peptide conjugates in the brain. The most therapeutically promising compounds could also be radiolabeled to assess their intracerebral stability and kinetics.
  • Experiment #2 Measure the number of glioma cells undergoing cell death, DNA damage, and DNA synthesis with amiloride amino acid and peptide conjugates of the present invention using histological and stereological methods.
  • Experiment #3 Determine correlation between tumor regions of glioma cell death and DNA damage with regions of persistent tumor acidosis and hypoxia.
  • Experiment #4 Determine correlation between tumor regions of glioma cell death and DNA damage with regions of persistent tumor acidosis and hypoxia.
  • EF5 can be perfused into tissues, including brain, and forms adducts under hypoxic conditions that are visualized in frozen sections using a commercial monoclonal antibody against EF5.
  • EF5 staining in human tumors is consistent with diffusion-limited hypoxia rather than acute hypoxia measured by HIF-1 (Evans et al, Amer. J. Clin. Oncol, 24:467-472 (2001)).
  • HIF-1 HIF-1
  • the maximal binding rate of oxygen to EF5 can be estimated by assuming an "average" oxygen dependence of binding for the contralateral normal cerebral hemisphere in conjunction with the tissue cube method (Koch, supra).
  • the best-fit approximation for existing data is an inverse relationship between binding and pO 2 , with binding decreasing 50-fold between 0.1% and 10% oxygen.
  • Experiment #5 Evaluate the neurotoxicities of the amiloride conjugates of the present invention using behaviorial assessments and neuropathological surveys.
  • Body weights and behavioral parameters can be assessed daily in drug-treated and vehicle-treated rats for 14 days. Standardized behavior tests, which include quantitative measures of vestibulomotor function, fine motor coordination, ambulation, and spatial memory can be used. A daily neurotoxicity behavioral sign checklist can also be performed to detect neurological signs of toxicity and seizures. Acquisition of spatial memory is particularly sensitive for detecting subtle drug toxicities. Body weight can be used as a measure of general health.
  • the surveyed brain regions can be influenced by symptomatology (e.g., ataxia, spasticity), but can include parasaggital and coronal tissue blocks of the nucleus caudatus, putamen, dentate gyrus, cerebellum, primary somatosensory cortex, cingulate gyrus, and brainstem regions that include the inferior olives, and the vestibular nuclear complex.
  • Assessment of brainstem white matter tracts with luxol fast blue staining can include the spinocerebellar, vestibulospinal, corticospinal, and spinothalamic tracts. Specialized stains for reactive asfrocytes, neuronal chromatolysis, etc. can be added if brain lesions are detected.
  • stains can include Fluoro-Jade to detect neuronal degeneration (Schmued et al, Brain Res., 751:37-46 (1997)) and GFAP immunostaining for glial fibrillary acidic protein as a sensitive detection for reactive glial responses. Analysis of the neuropathology slides can be performed in double-blind experiments.
  • Experiment #6 Amiloride conjugates of the present invention that are efficacious in the xenograft models can be injected into the tail veins of control rats. Blood and brain levels can be measured using LC-MS and can be subsequently radiolabeled, as needed, for more precise quantitation.
  • a particular level of sensitivity i.e., detection of O.Olpmol of amiloride per gram of brain tissue
  • detection of O.Olpmol of amiloride per gram of brain tissue can be adequate to measure levels of amiloride conjugates that accumulate in the brain and cerebrospinal fluid during intracerebral administration. This information is useful for subsequent studies examining neurotoxicity and for evaluation of whether the conjugates effectively partition across the blood brain barrier following adminisfration into the internal jugular vein. If an effective conjugate is identified, radiolabeling can be performed to accurately assess the transport of the conjugate from blood to the brain as well as its stability within the brain.
  • Sample sizes for the experiments can be determined by power analysis using an acceptable level of statistical power (80) to reliably detect treatment effects.
  • Alpha level for Type I error can be set at 0.05 for rejecting null hypotheses.
  • Suppression of tumor volume by NHEl inhibitors, stereological counts of cytological markers, and dose- response effects of individual drugs can be analyzed with one-way (Treatment Group) ANOVA followed by post hoc Dunnett's test for comparison of individual treatments to control. Differences in survival duration between confrols and drug-treated groups for in vivo experiments can be compared using the Cox-Mantel analysis.
  • Rats 250-280 gm
  • Rats can be intubated with 4% isoflurane and air:O 2 (2:1), maintained on 2% isoflurane, and placed into a Kopf stereotactic apparatus.
  • Glioma cells can be harvested at 80% confluence, trypsinized, and then washed three times in sterile, isotonic phosphate buffered saline. Cells can be counted in a hemocytometer and diluted to a final concentration of lxlO 5 cells per ⁇ l.
  • 5 ⁇ l of glioma cells can be stereotaxically injected into a 0.5mm pocket made by a 23 gauge needle in the left anterior corpus striatum (-1 mm bregma, +4 mm left lateral, -5.0 mm depth) under sterile conditions in a laminar flow hood.
  • the rats Prior to imaging, the rats can be administered 0.5cc of Omniscan gadodiamide infraperitoneally (Nycomed, Princeton, NJ).
  • the rats can be anesthetized by face mask with a 1.5% isoflurane and 0.5 1/min oxygen, placed prone in a Lucite holder, and secured by thin strips of adhesive tapes.
  • a gradient recalled echo sequence can be obtained which furnishes a single slice in sagittal, coronal, and transverse orientations ("triplot”) and which serves as a scout image to ensure proper positioning of the animal.
  • Spectroscopic images can be obtained with a 7 Tesla (300 MHz) Bruker BIOSPEC 70/20 system with a 210 mm horizontal bore equipped with B-GA12 shim coils driven by Bruker Shim Power Supply with a maximum of 2A of current for each shim.
  • SI 16 birdcage design resonator coil maximum current, 100A; maximum voltage, 150N
  • the 2mm slice thickness encompasses a 64mm by 64mm field on a 128 x 128 matrix, and renders 25mm 2 per pixel resolution.
  • Multiple contiguous slices separated by 1mm can be collected using 3 sine pulses of 2 msec duration, which cover the entire tumor in one scan.
  • the average scan time can be approximately 60 sec for the entire Tl weighted protocol.
  • Diffusion weighted images can be obtained using a spin echo sequence that can be modified to include the diffusion sensitizing gradients and images acquired in the same set of slices as in the Tl weighted sequences.
  • Four sets of diffusion-weighted images can be obtained using the following 'b' values: 11.942, 174.275, 549.771, and 1138.429 sec/mm 2 .
  • the TR/TE can be set at 3600/60 msec and the total collection time can be 30min.
  • the gradient separation (big delta) time can be 20 msec and the value of small delta (gradient on time) can be 10 msec.
  • Data can be processed mostly using Paravision (Bruker) on a silicon graphics imaging workstation.
  • Apparent diffusion constant (ADC) maps for all the slices can be calculated with the Paravision software using a two parameter exponential fit (Roberts et al, Eur. J. Radiol, 45:185-194 (2003)).
  • the cytological markers have been well established in several models of brain injury and in glioma xenografts. Confirmatory markers can be used on adjacent brain sections when possible to assess their relative sensitivities.
  • the TUNEL assay is a specific but late marker of apoptosis that has reduced sensitivity in vivo.
  • staurosporine-induced apoptosis in astrocytes and gliomas that is associated with annexin V binding can be examined. Therefore, the sensitivities of annexin V binding with the TUNEL assay in vivo can be compared. Errors in detection sensitivities of these cytological markers are systematic as the indices of apoptosis, necrosis, and proliferation between the treatment and control groups can be compared.
  • the stains used for cytological staining can include: (1) Nissl stain, which provides a high-contrast image of glioma cells for determination of cell volume; (2) Bromodeoxyuridine (BrdU) labeling, in which rats can be injected infraperitoneally with BrdU (60 mg/kg) 1 h before intracardiac perfusion with 4% paraformaldehyde to label . proliferating cells and 4 ⁇ m sections can be immunostained with a FITC-labeled, polyclonal antibody against GFAP (1:10,000) followed by a cyan-labeled, polyclonal antibody against BrdU (1:1000) as described (Reilly et al, Exp.
  • H2Ax immunostain which is performed with a purified mouse monoclonal antibody against a peptide fragment (amino acids 178-194) of human H2Ax.
  • necrotic identification of necrotic cells permits semi- automated laser microscope cytomefry and the fluorescent nuclear stain Hoescht 3222 or Sytox Green has been used to identify apoptotic and necrotic glioma cells freated with staurosporine or amiloride, respectively.
  • a comparison on alternate slides of the necrotic cells identified with Sytox Green with those identified by hematoxylin and eosin staining can be performed.
  • Rats can be deeply anesthetized with sodium pentobarbitol (75mg/kg, i.p.) followed by intracardiac perfusion with phosphate buffer saline followed by 4% buffered paraformaldehyde. Brains can be removed and postfixed in 2% paraformaldehyde at 4°C for 24 h and then paraffin embedded or placed into sucrose prior to storage at -80°C. Postfixed brains can be cryoprotected in sucrose and sectioned at 40 ⁇ m on a freezing stage microtome. These thicker sections can be stained with a high-contrast Nissl stain and tumor volume of sequential sections can then be calculated by the Cavalieri method. Unbiased stereological techniques can be used to estimate tumor volume and cell density.
  • Tumor volumes can be calculated by the Cavalieri method. This method estimates the volume of a structure (e.g., glial tumor) by measuring the area of the structure in a number of evenly spaced "two-dimensional" sections. For an in vivo tumor model, the procedure involves a systematically random collection of 10 sections evenly spaced through the entire tumor. To perform this, the brain is cut into 40 ⁇ m coronal sections and every section is collected to encompass the entire tumor. When the most anterior portion of the tumor becomes visible in the series of sections, a dye is thrown to determine if the first, second, third, fourth, or fifth section from that point should be the initial section saved for staining and area analysis. Henceforth, every tenth section is stained and the tumor area measured.
  • a structure e.g., glial tumor
  • Tumor area is estimated with suitable precision by applying to each section a point grid with a known area associated with each point (a/p).
  • the grid generation and volume calculations can be performed with Stereologer (Version 1.0) software on a Windows-based system connected to a Nikon E600 microscope with motorized xyz stage controller (ASI MS- 2000). Tumor volumes can be described as mean volumes (mm 3 ) ⁇ S.D.
  • Unbiased cell counting can be performed using the optical fractionator stereological method. This method is based on the principle that the number of cells in a whole object (e.g., glioma) can be accurately estimated by counting the number of cells in a known fraction of the object.
  • the volume of the area of interest is first calculated by the Cavalieri method described above.
  • the Stereologer software divides the area of interest on each slide into "dissectors," which are small volumes of tissue (e.g., 25 x 25 x 20 ⁇ m) from which the cell counts are made. It is only necessary to count approximately 10% of the dissectors to arrive at accurate estimates of the number of cells in the entire object. The software randomly selects the dissectors to be counted.
  • EF5 perfusion EF5 can be perfused in deeply anethesized animals pretreated 3 h before with BrdU and then the brains can be immediately frozen. Frozen sections can be immunostained for EF5 binding and analyzed by a sensitive CCD camera. The entire optical system, including the CCD camera, can be calibrated by an absolute fluorescence standard (dye in hemocytometer). The maximum binding rate can be estimated using the tissue cube method by calculating an "average" oxygen dependence of the contralateral normal brain hemisphere. The best-fit approximation for existing data can be an inverse relationship between binding and pO 2 , with binding decreasing 50-fold between 0.1% and 10% oxygen. Using these methods, an estimate of the minimum pO 2 (i. e., maximum binding) in experimental rodent and human tumors can be determined.
  • Neutral red can be perfused in animals pretreated 3 h before with BrdU and then the brains can be immediately frozen using the liquid nitrogen funnel technique. Cryostat frozen sections can be visualized and photographed by a CCD camera for semiquantitative photometry (Hoffman et al, id; Chavez et al, J. Neurosci, 22:8922- 8831 (2002)). The possibility that deeply anesthetized animals can be perfused with EF5 followed by neutral red prior to sacrifice can be investigated. Neutral red sections can be digitally imaged and subsequently immunostained for EF5 using an anti-EF5 monoclonal antibody.
  • Beam Walk Components of fine motor coordination can be assessed using a beam-walking task. Twenty-four hours prior to tumor implantation, rats can be trained to escape a bright light and loud white noise by traversing an elevated narrow wooden beam (2.5 x 100.0 cm) to enter a darkened goal box at the opposite end of the beam. Performance for each day can be the mean latency of three trials to traverse the beam.
  • the test apparatus consists of a large white circular tank (220cm diameter by 60cm high) filled with water to a depth of 21cm. Water temperature can be maintained at 26 ⁇ 2°C.
  • a transparent circular escape platform (12cm diameter, 19cm high) can be placed in fixed position in the tank 2cm below the water surface. Consistent visual cues can be located in the test room outside of the maze. Each trial can be started by placing the rat in the water close to and facing the wall of the tank in one of the four cardinal start locations. Rats can be allowed 120 sec to find and mount the escape platform. Rats can receive 4 trials/day over 5 consecutive days. Data can be recorded using a video tracking system (Poly-Track, San Diego
  • Body weight, beam walk, and Morris water maze assessments can be analyzed with repeated measures ANONA (Treatment Group x Days) with assessment days as the repeated variable within subjects.
  • ANONA Treatment Group x Days
  • post hoc Dunnett's test for comparison of individual treatments to control can be performed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions contenant des conjugués d'acides aminés et de peptides d'amiloride. L'invention concerne également des méthodes efficaces d'administration des conjugués d'amiloride de la présente invention dans le traitement du cancer, ou d'une maladie ou d'un trouble du système nerveux central, ou dans la prévention ou la réduction d'une lésion ischémique consécutive à la perfusion. L'invention concerne, de plus, des kits utilisés dans le traitement d'une maladie ou d'un trouble du système nerveux central, ou dans la prévention ou la réduction d'une lésion ischémique consécutive à la perfusion à l'aide des conjugués d'amiloride de la présente invention.
PCT/US2005/001564 2004-01-23 2005-01-21 Conjugues d'acides amines et de peptides d'amiloride et methodes d'utilisation WO2005073247A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53897204P 2004-01-23 2004-01-23
US60/538,972 2004-01-23

Publications (1)

Publication Number Publication Date
WO2005073247A1 true WO2005073247A1 (fr) 2005-08-11

Family

ID=34826029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001564 WO2005073247A1 (fr) 2004-01-23 2005-01-21 Conjugues d'acides amines et de peptides d'amiloride et methodes d'utilisation

Country Status (2)

Country Link
US (2) US7863415B2 (fr)
WO (1) WO2005073247A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081863A1 (fr) * 2016-11-04 2018-05-11 University Of Wollongong Dérivés à substitution en position 6 de l'hexaméthylène amiloride en tant qu'inhibiteurs de upa et leurs utilisations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185153A4 (fr) * 2007-08-03 2012-02-29 Univ California Inhibiteurs d'activateur du plasminogène de type urokinase intracellulaire et procédés d'utilisation
WO2010151852A2 (fr) * 2009-06-26 2010-12-29 University Of Florida Research Foundation, Inc. Inhibiteurs de la protéase, compositions les comprenant et procédés d'utilisation
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
CN105259286B (zh) * 2015-10-26 2017-03-29 上海华拓医药科技发展有限公司 磷酸肌酸二钠盐中杂质化合物的高效液相色谱检测方法
CN112867492A (zh) * 2018-06-01 2021-05-28 帕诺治疗股份有限公司 治疗癌症的方法
AU2022306352A1 (en) * 2021-07-08 2024-01-25 Lung Therapeutics, Llc Epithelial sodium channel (enac) inhibitor conjugates and methods for use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PALANDOKEN ET AL: "Amiloride peptide conjugates: prodrugs for sodium-proton exchange inhibition.", J. PHARMACOL. EXP. THER., vol. 312, March 2005 (2005-03-01), pages 961 - 967, XP008048199 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081863A1 (fr) * 2016-11-04 2018-05-11 University Of Wollongong Dérivés à substitution en position 6 de l'hexaméthylène amiloride en tant qu'inhibiteurs de upa et leurs utilisations

Also Published As

Publication number Publication date
US20060160746A1 (en) 2006-07-20
US20110195907A1 (en) 2011-08-11
US7863415B2 (en) 2011-01-04

Similar Documents

Publication Publication Date Title
US7635682B2 (en) Tumor activated prodrugs
US20110195907A1 (en) Amino acid and peptide conjugates of amiloride and methods of use thereof
Mazel et al. Doxorubicin-peptide conjugates overcome multidrug resistance
Orbán et al. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin–GnRH-III bioconjugates and DNA-binding properties of daunorubicin–amino acid metabolites
US6265540B1 (en) Tissue specific prodrug
KR101759261B1 (ko) 유도형질로 활성화되는 다기능성 항암제 전구체, 이의 제조방법 및 이의 용도
US7217688B2 (en) Methods and compositions for derepression of IAP-inhibited caspase
JP5384342B2 (ja) 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド
AU2010274799B2 (en) Cyclosporin conjugates
US20060258581A1 (en) Methods and composition for derepressions of IAP-inhibited caspase
KR101171381B1 (ko) 암세포에 특이적인 활성을 갖는 신규 펩타이드 항암제
US20090227521A1 (en) Use of compounds in the treatment of ischemia and neurodegeneration
JP2005510569A (ja) Ｉａｐ阻害カスパーゼの活性化のための方法および組成物
WO2006042282A2 (fr) Inhibiteurs peptidiques diriges contre la seprase
Dugal-Tessier et al. Synthesis and evaluation of dolastatin 10 analogues containing heteroatoms on the amino acid side chains
Pignatello et al. Lipophilic methotrexate conjugates with antitumor activity
EP1210098A1 (fr) Amelioration de la fixation cellulaire
US8546322B2 (en) Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof
US20030133927A1 (en) Conjugates useful in the treatment of prostate cancer
EP3269727B1 (fr) Agent pharmaceutique à base de polypeptide de protéine x du virus de l'hépatite b
US20020142966A1 (en) Inhibitors of the E2F-1/cyclin interaction for cancer therapy
US20090043099A1 (en) Methods and compositions for derepression of IAP-inhibited caspase
US20110183358A1 (en) Methods and compositions for derepression of iap-inhibited caspase
EP1593686B1 (fr) Peptides antinéoplastiques
US20050119176A1 (en) Methods and compositions for derepression of IAP-inhibited caspase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase